Articles
-
All
-
Scientific Reviews
-
EDM
-
Blog
-
Most Recent
-
Oldest
-
SARS-CoV-2 contains four main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. All the proteins and subcellular structures of CoVs are promising targets for SARS-CoV-2 research.
-
The concept of ADC can be traced back to the early 1900s, It is a visionary magic bullet that could deliver a toxic drug to certain malignant cells without affecting other normal tissues. Now, it seems that a golden age of ADC drug development is coming.
-
PROTAC, which exploit the ubiquitin-proteasome pathway to specifically degrade target proteins. PROTACs not only solve the problem of undruggability but they also have other advantages compared to traditional drug targeting strategies.
-
PROTAC — Target Selection and Design
2022-07-08
A PROTAC molecule consists of three components: a target protein binding ligand, an E3 ligase ligand, and a linker connecting these two moieties. Here, we will discuss the conventional approaches for the rational design of PROTAC molecules. -
BacPROTACs is composed of a POI ligand, a chemical linker and a ClpCNTD anchor. BacPROTACs can induce in vitro and in vivo degradation of non-eukaryotic proteins in bacteria without the ubiquitin proteasome system.
-
Tsvetkov et al. published in Science and demonstrated a copper-induced programmed cell death — Cuproptosis. As a novel programmed cell death, excess copper triggers abnormal aggregation of lipoylated proteins in TCA cycle and clearance of Fe-S cluster proteins, ultimately leading to cell death.
-
A comprehensive explanation of ferroptosis
2022-09-15
Ferroptosis is a new type of RCD that depends on iron and characterized by the accumulation of lipid peroxides. In this article, we will pay our attention on ferroptosis and briefly discusses its mechanism. -
It's has been proved that p53, as a tumor suppressor gene and immune guardian, may become a destroyer through its own mutation. Moreover, the mechanism of p53 was found to be related to ferroptosis. This article mainly explores the mechanism between p53 and ferroptosis in detail.
-
Autophagy, derived from the Greek meaning "eating of self", plays an indispensable role in maintaining homeostasis. p27 is an inhibitor of cyclin CDKs, but how p27 regulates autophagy remains unknown. This article will cover the mechanism of autophagy and p27-related cell cycle regulation.
-
CMA (chaperone-mediated autophagy) plays an essential role in maintaining neuronal protein stability and preventing neurodegeneration. In this article, we will comprehensively clarify the role of CMA in the occurrence and development of neurodegenerative diseases.
-
TME (Tumor microenvironment) is considered as a complex integrated system, composed of cellular components such as tumor cells and immune cells, as well as non-cellular components such as ECM and cytokines. According to the spatial distribution of immune cells in TME, "hot" and "cold" TME will be explained in this article.
-
Efferocytosis is the process in which phagocytes remove programmed dead cells. It prevents secondary necrosis of dying cells from releasing harmful cell contents (such as oxides and proteases) that may cause inflammation. Here, we will introduce three stages of efferocytosis: Find, Eat, Digest.
-
PROTAC - Design Strategy for Targeting
2023-04-23
Protein degradation targeting chimera (PROTAC) is a technology that uses the ubiquitin proteasome pathway to silent target protein. However, PROTAC still has problems such as solubility, membrane permeability, and selectivity. In this article, we have summarized three strategies for optimization: light-controlled linker, PAC molecule, and specific E3 ligase. -
Necroptosis, also known as necroptosis, is a form of regulated necrotizing cell death mediated by RIP1 and RIP3 kinases. Necroptosis is a process that prevents the self-destruction of activated cells that are blocked by apoptosis. Necroptosis plays a tumor suppressor role in most cases. It may provide benefits in the researches of a variety of human diseases involving immune inflammation and cell death.
-
Mitophagy:Mechanisms and Detection
2023-05-25
About 60 years ago, Christian de Duve first used the term "autophagy" to describe his observation of the degradation of mitochondria and other intracellular structures in lysosomes of rat liver. Over the years, autophagy has remained a beloved topic of research by the National Natural Science Foundation of China (NSFC).Today, let's talk about mitochondrial autophagy. -
HLA-E, A Novel Immune Checkpoint
2023-06-29
Immune checkpoints have immunosuppressive functions. It can be used in the research of tumor immunotherapy. In this article, we introduce a new paper entitled "Immune checkpoint HLA-E: CD94 - NKG2Amediates evasion of circulating tumor cells from NK cell surveillance "research paper. -
WHO's Q2 drug list has been updated. Let's take you through the list of the most noteworthy small molecule drugs that we should pay attention to.
-
FDA Approved Drug List!
2023-09-14
In the first half of 2023 (as of June 27), the FDA approved 26 new drugs, let's take you learn about it through the article. -
IHC is an indispensable technique for studying tissue morphology and in situ antigen expression, but usually only one or two antigens in tissues can be stained for analysis. It cannot judge the results more intuitively. Today, Little M will introduce you to the upgraded version mlHC.
-
A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening of diseases such as cancer, infectious diseases, and rare diseases.
-
FDA Annual Review | Record-breaking number of new drug approvals in 2023!
-
KRAS, a gene we've heard so much about, has quickly risen to fame after shedding its "undruggable" label. After reading numerous articles, it's easy to feel overwhelmed and wonder: What exactly should we know about this often-discussed but previously "undruggable" target KRAS?
-
Compound Screening Guide!
2024-03-15
How to use compound library? How to design an experiment if you buy a compound library? Want a specific experimental protocol? This article will introduce popular experimental techniques and provide new ideas for publishing high level literature. -
Wnt/β-catenin and tumor EMT
2024-03-18
Epithelial-Mesenchymal Transition (EMT) is closely related to the plasticity of tumor cells and is a necessary process for tumor metastasis. Wnt/β-catenin is one of the main actors involved in the EMT process. Today, we’re here to popularize the tumor EMT and Wnt/β-catenin pathway~ -
The 2024 AACR meeting concluded successfully in California, USA. Which antitumor drugs stole the show at this conference?
-
Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine in 2023 for their groundbreaking work in nucleoside modification, which paved the way for the creation of successful mRNA vaccines to fight against COVID-19. Let's now delve into the complete process of mRNA vaccine development.
-
Science | A "new" mechanism for non-ubiquitinated Midnolin-proteasomal degradation pathway
2024-04-26
“ubiquitin-mediated protein degradation” won the Nobel Prize in Chemistry in 2004! In fact, proteasomes degrade not only ubiquitinated proteins but also non-ubiquitinated ones. The mechanism remains shrouded in mystery. After reading this piece today, you might have a lightbulb moment! -
Exosomes, which won the Nobel Prize in 2013, are still a research hotspot in the national natural sciences, and their popularity has only increased over the past decade (in 2022, they still rank 5th in the national natural sciences hotspots!). Why have exosomes become the darling of scientific research? Let's take a look together~
-
How important is the compound library? It connects to drug screening on one end and leads to lead compound modifications on the other, serving as one of the sources of new drug development.
-
Degrade target proteins through the autophagy-lysosome pathway including LYTAC, AUTAC, and ATTEC have gained increasing attention in recent years due to their significant research potential!
-
Antibodies!
2024-07-26
Today, We introduce antibodies for everyone! -
What Are Popular Anti-tumor Drug Targets?
2024-08-20
The rapid development of targeted anti-cancer drugs has spurred diverse research across various modalities. These include small molecules, monoclonal antibodies (mAbs), cell immunotherapies, antibody-drug conjugates (ADCs), and PROTACs (proteolysis targeting chimeras). -
Cuproptosis, How much do you know?
2024-08-22
Cells die in a variety of ways, including apoptosis, pyroptosis, necrosis, and ferroptosis......And, of course, cuproptosis. So, how much do you know about cuproptosis? -
Virtual Screening and New Uses for Old Drugs
2024-09-17
With the advancement of medical science, drug screening against various disease targets has become the fundamental strategy for drug development. Currently, computer-based virtual screening techniques are emerging in the field of new drug research due to their efficiency and low cost. Let's explore it today! -
Recently, Mol Cell reported the discovery of the first ferroptosis marker, Hyperoxidized PRDX3! Let’s take a look together~
-
Cuproptosis's Knowledge Points!
2024-09-25
With the establishment of the cuproptosis mechanism related research has attracted more and more attention from major journals. Expect to use the sharp sword of cuproptosis to stab the tumor cells. -
2024 Nobel Prize Announcements! Curious about the details? Click to dive into the exciting developments!
-
A New Form of Cell Death: PANoptosis!
-
We are thrilled to share the latest advancements in AI technology as highlighted in this insightful article. From groundbreaking innovations to transformative applications, the future of AI is brighter than ever!
-
Autophagy is a fundamental process that degrades various components within the cell.
-
nside cells, the homeostasis and degradation of proteins is a precisely regulated process. If proteins cannot be degraded in time, it may lead to the occurrence of various diseases such as neurodegenerative diseases and cancer. This article will tell you the process of how proteins are recognized, labeled and then degraded!
-
This article will walk you through the remarkable impacts of anti-payload antibodies, delving into how these molecules are revolutionizing drug development and biological research!
-
Cell Migration vs. Invasion: Differences Revealed by Scratch Assays and Transwell Experiments
2025-05-30
In scientific research, cell migration and invasion are crucial for understanding many important biological processes. This article delves into commonly used detection methods: the scratch assay and Transwell migration/invasion assay. -
How should drug screening experiments be conducted? How can we ensure the accuracy of the lead compounds identified? This article will take you through how MCE's clients conduct drug screening experiments.
-
In this issue, we will conduct an in-depth interpretation from the dimensions of nanoparticle design, mechanism of action, in vivo and in vitro efficacy, and immune regulation, revealing how this research brings new hope for the treatment of invasive tumors through interdisciplinary innovation!
-
IHC, ICC, IF Techniques: A Practical Guide
2025-07-25
Confused About IHC/ICC/IF? Why Does Immunostaining Seem So Complicated? Read This Now! Master Immunostaining with Confidence! -
HTS Breakthroughs Powered by MCE Libraries
2025-08-13
Key High-Throughput Screening Breakthroughs of 2024 Featuring MCE -
Encountering challenges with the high costs and long timelines of drug screening? Have a defined target but remain uncertain how to efficiently identify active molecules? Unsure how to validate hits generated from virtual screening? The ‘Winning Combination’ of drug screening offers a powerful solution to address these critical obstacles.
-
This detailed guide outlines the standardized experimental protocols for multiplex immunohistochemistry (mIHC), systematically summarizes common technical issues encountered during sample preparation, staining and imaging processes, and provides practical troubleshooting solutions to ensure reliable and reproducible results in biomedical research and clinical sample analysis.
-
Exosomes—natural nanoscale carriers—are revolutionizing targeted therapy. This article uncovers the science behind their precision in drug delivery.
-
Cracking the PROTAC Permeability Barrier: CD36-Mediated Endocytosis as a Potential Breakthrough
2025-12-03
This article provides an in-depth analysis of cutting-edge literature revealing CD36 as a key mediator of cellular uptake for PROTACs and bRO5 compounds. By structurally optimizing PROTAC molecules to enhance their affinity for CD36, membrane permeability can be markedly improved, leading to significantly enhanced antitumor efficacy. -
A November 2025 Cell study discovers Mitoxyperilysis, a new mTOR-regulated, caspase-independent cell death pathway driven by innate immune and metabolic dysregulation via mitochondrial-plasma membrane contact and oxidative damage, and verifies its potential to induce tumor necrosis for cancer therapy with key regulators including BAX, BAK1 and BID.
-
This paper elaborates on cytokines for culturing major immune cells, their regulatory roles, recombinant cytokines' merits and MCE’s related high-quality products.
-
This article walks you through the experimental design and workflow of flow cytometry, delivering a clear, dynamic, and professional overview to elevate your research.
-
Molecular glue degraders have evolved from a serendipitous observation to one of the most dynamic and transformative fields in biomedical research.
-
This review introduces the major forms of programmed cell death, with a focus on the molecular mechanisms of ferroptosis and the methods used for its detection.
-
Targeting the ‘Undruggable’ with PROTACs
2025-06-18
This review introduces the fundamental principles and mechanisms of PROTACs, highlights recent advances in molecular design and clinical development, and discusses emerging opportunities and remaining challenges in targeted protein degradation. -
This review presents an overview of antibody–drug conjugates from design principles and antitumor mechanisms to structural innovations, clinical progress, and future development prospects.
-
This review explores mechanisms and strategies for modulating the gut microbiota to enhance cancer immunotherapy, providing insights to improve therapeutic efficacy.
-
Combating Immune Evasion in Cancer
2025-10-15
This review summarizes the mechanisms by which tumors evade immune surveillance and discusses therapeutic strategies to restore antitumor immunity. -
This review provides a practical guide to the fundamental mechanisms, regulatory pathways, and detection methods of pyroptosis.
-
Understanding In Vivo CAR-T Cell Therapy
2026-01-22
This review provides a comprehensive overview of in vivo CAR-T therapy, covering technical platforms, clinical translation, and key challenges such as gene delivery and immunogenicity. -
Explore ADC evolution, immune combination strategies, and clinical advances at the intersection of targeted therapy and immunotherapy.
-
Summarize LLPS principles, regulatory mechanisms, experimental strategies, and pathological roles to inspire mechanism-driven research and translational applications.
-
Tumor Organoid-Immune Cell Co-Culture Models: Advances, Applications, and Future Directions
2026-05-07
Summarize technical strategies, application advances, and future directions of tumor organoid–immune co-culture systems. -
Review mechanisms, major challenges, and efficacy-enhancing strategies of TCR-T therapy in solid tumors, with implications for future research and clinical translation.
-
Review the mechanisms, mitochondrial regulation, disease relevance, and translational opportunities of the NLRP3–STING axis in neuroinflammation.
-
Breaking Immune Resistance in Colorectal Cancer: From Molecular Mechanisms to Precision Therapy
2026-06-25
Explore CRC molecular subtypes, immune landscapes, resistance mechanisms, and emerging precision strategies for improving outcomes across distinct subtypes. -
Review the evolution of molecular glues from serendipitous discovery to rational design, highlighting how emerging targets and advances in screening, proteomics, structural biology, and AI are expanding the druggable proteome.
-
R916562, a dual Axl/VEGF-R2 inhibitor, could be a potential anti-angiogenic and anti-metastatic drug for cancer chemotherapy.
-
Role of PRMT7 Probe SGC3027 in Cancer
2019-03-27
SGC3027 is the first potent, selective and cell active chemical probe for PRMT7. SGC3027 is also a pro-drug, which converts to the active compound SGC8158 -
Alofanib, An Allosteric Inhibitor of FGFR2
2019-03-28
Alofanib is an allosteric inhibitor of FGFR2 and inhibits FGF-mediated proliferation with GI50s of 16-370 nM, showing pronounced antitumor activity. -
AZD5991, a macrocyclic molecule with high selectivity for Mcl-1, reduces Mcl-1 protein in AZD5991-sensitive but not in AZD5991-resistant MM cell lines.
-
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with anti-tumor activity in acute leukemia and breast cancer cell lines.
-
CCB02 is an tubulin binder and has potential in the therapy of cancer cells with extra centrosomes. CCB02 also activates spindle assembly checkpoint.
-
H3B-5942 is a selective and irreversible estrogen receptor covalent antagonist, inactivates both ERαWT and ERα mutation.
-
A Lead PROTAC BRD9 Chemical Degrader
2019-04-06
PROTAC BRD9 Degrader-1 is a lead PROTAC BRD9 chemical degrader and a selective probe useful for the study of BAF complex biology. -
HS-1371 is a Small Molecule RIP3 Inhibitor
2019-04-09
HS-1371 is a novel kinase inhibitor of RIP3-mediated necroptosis, showing an inhibitory effect on S227 auto-phosphorylation of RIP3 at the basal level. -
MK-0429 is An Oral Integrin (αvβ3) Inhibitor
2019-04-11
MK-0429, an orally active αvβ3 inhibitor, is a potential therapeutic agent for the prevention of kidney fibrosis, melanoma and osteoporosis. -
PhiKan 083 is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a Kd of 167 μM.
-
Novel Greatwall Kinase Inhibitor GKI-1
2019-04-13
GKI-1, a GWL inhibitor, robustly inhibited ROCK1 with an IC50 of ~11 μM, but only weakly affected PKA and had no observable inhibition towards CDK2. -
SSE15206 is a microtubule polymerization inhibitor, with a GI50 of 197 nM in HCT116 cells. Causes aberrant mitosis resulting in G2/M arrest.
-
Erteberel is a Selective ERβ Agonist
2019-04-16
Erteberel (LY500307) is a synthetic, nonsteroidal estrogen which acts as a selective ERβ agonist and under development for the treatment of schizophrenia. -
MBQ-167 is a dual Rac/Cdc42 inhibitor in in metastatic cancer, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.
-
PRN1008 is a Reversible Covalent and Oral Active Inhibitor of Bruton’s Tyrosine Kinase (BTK)
2019-04-18
PRN1008 is a selective, reversible covalent and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM. -
Y06036 is a potent and selective BET inhibitor for potential treatment of castration-resistant prostate cancer. With nanomolar inhibition.
-
JNJ-64619178 is a selective and pseudo-irreversible PRMT5 inhibitor with an IC50 of 0.14 nM. Has potent Activity In Lung Cancer.
-
Cevipabulin is a microtubule-active compound and inhibits the binding of [3H] vinblastine to tubulin, with an IC50 of 18-40 nM for in human tumor cell line.
-
BTR-1 potently inhibits cell growth. It induces S phase arrest, affects DNA replication. Dose-dependently induces cytotoxicity in leukemic cell lines.
-
TAK-828F is a potent, selective and orally active retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist. TAK-828F inhibits IL-17A cytokine expression and reduces symptoms of autoimmune encephalomyelitis mice.
-
Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM. Antitumor activity.
-
NRX-252262 is a β-catenin:β-TrCP interaction enhancer, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM
-
TAK-981 is a selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities
-
TD-428 is a Highly Specific BRD4 Degrader
2019-04-29
TD-428, a immunomodulatory drug analog, is a highly specific BRD4 degrader with a DC50 of 0.32 nM. TD-428 reduces c-Myc levels more efficiently than JQ1. -
CB-6644 is a selective non-ATP-competitive inhibitor of the RUVBL1/2 complex. CB-6644 significantly reduces tumor growth without obvious toxicity.
-
A1874 is a nutlin-based and BRD4-degrading PROTAC with a DC50 of 32 nM. Effective in inhibiting many cancer cell lines proliferation
-
NSC 228155 is a activator of EGFR and a potent inhibitor of KIX-KID interaction. NSC 228155 shows excellent anti-tumor activity.
-
MM-589 is an inhibitor of WDR5 and MLL protein-protein interaction. Binds to WDR5 (IC50=0.90 nM) and inhibits the MLL H3K4 methyltransferase activity.
-
USL311 is a selective CXCR4 antagonist, which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4. Anti-tumor activity.
-
JI051 is a stabilizer for the Hes1-PHB2 interaction, induces cell-cycle arrest by inhibiting the Notch downstream effector gene Hes1.
-
CFI-402257 is a highly selective and oral active TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK. CFI-402257 has potential to treat ovary cancer and TNBC.
-
RIPGBM is a selective inducer of apoptosis in glioblastoma multiforme (GBM) cancer stem cells (CSCs) with an EC50 less than 500 nM.
-
IWP-O1, a Highly Potent Porcupine Inhibitor, Functions by Preventing the Secretion of Wnt Proteins
2019-06-03
IWP-O1 is a Porcupine (Porcn) inhibitor, with an EC50 of 80 pM in L-Wnt-STF cells. IWP-O1 functions by preventing the secretion of Wnt proteins[ -
PF-06465469 is a Covalent Inhibitor of ITK
2019-06-08
PF-06465469 is a potent and covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 inhibits MEK1/2 or AKT phosphorylation. -
Riviciclib is a Potent CDKs Inhibitor
2019-06-09
Riviciclib P276-00 free base) is a potent CDK inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively -
CBS9106, a Reversible Oral CRM1 Inhibitor, Causes Arrest of the Cell Cycle and Induces Apoptosis
2019-06-14
CBS9106 (SL-801) is a reversible oral CRM1 inhibitor antitumor activities. CBS9106 causes arrest of the cell cycle and induces apoptosis. -
NU6140 is a selective CDK2-cyclin A inhibitor (IC50, 0.41 μM). NU6140 also potently inhibits Aurora A and Aurora B, with IC50s of 67 and 35 nM, respectively
-
S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt). S18-000003 ameliorates psoriasis-like lesions in vivo. S18-000003 can be used for the research of skin inflammatory diseases.
-
TH34, an HDAC6/8/10 inhibitor with IC50s of 4.6 μM, 1.9 μM, and 7.7 μM respectively, shows high selectivity over HDAC1/2/3.
-
Alisertib (MLN 8237) is an oral active and selective Aurora A kinase inhibitor with an IC50 of 1.2 nM. To treat hematologic malignancies and solid tumors.
-
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3). AMG 487 has potential to treat metastatic cancer.
-
S55746 (BLC201) is an orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM.. S55746 (BLC201) has antitumor activity with low toxicity.
-
WYC-209 is a retinoic acid receptor (RAR) agonist. WYC-209 induces apoptosis primarily via the caspase 3 pathway (IC50 = 0.19 μM for mTRCs).
-
M-89 is a specific menin inhibitor, with a Kd of 1.4 nM. M-89 inhibits the Menin-MLL protein-protein interaction and has potential to treat MLL leukemia.
-
MBM-55 is a potent, selective Nek2 inhibitor with an IC50 of 1 nM. MBM-55 shows antitumor activities and induces cell cycle arrest and apoptosis.
-
ACBI1 is a PROTAC Degrader of BAF Complex
2019-08-07
ACBI1 is a potent PROTAC degrader of BAF ATPase subunits SMARCA2, SMARCA4 and PBRM1, with DC50s of 6 nM, 11 nM and 32 nM in MV-4-11 cells, respectively. -
VERU-111 (ABI-231) is a potent and orally bioavailable α and β tubulin inhibitor, which displays strong antiproliferative activity.
-
MSX-122 is an orally active partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions. MSX-122 has both anti-tumor and anti-metastasis activities.
-
MPT0B392 Induces Apoptosis via Inhibiting Tubulin Polymerization and Inducing c-JNK Activation
2019-08-16
MPT0B392 is a novel microtubule depolymerizing agent that triggers induction of the mitotic arrest and induces JNK activation, leading to apoptosis. -
BJE6-106 is a selective PKCδ inhibitor with an IC50 of 0.05 μM and targets selectivity over PKCα. BJE6-106 induces caspase-dependent apoptosis.
-
MS31 is a highly selective spindlin 1 inhibitor, which inhibits the interactions between SPIN1 and H3K4me3. MS31 is not toxic to nontumorigenic cells.
-
AAPK-25 is a potent and selective Aurora kinases and Polo-like Kinases (PLK) dual inhibitor, which shows anti-tumor activity.
-
WZ811 is an Orally Active CXCR4 Antagonist
2019-09-07
WZ811 is an orally active, highly potent competitive antagonist of CXCR4, which inhibits chronic lymphocytic leukemia progression and tumorigenesis. -
SGC-iMLLT is a potent, selective MLLT1/3-histone interactions inhibitor and shows high binding activity towards MLLT1 YEATS domain and MLLT3 YD.
-
RU-302 is a pan-TAM inhibitor that blocks the TAM Ig1 ectodomain and the Gas6 Lg domain interaction. RU-302 blocks Gas6-inducible Axl receptor activation.
-
BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor and sensitizes apoptosis by in breast cancer.
-
BPK-29 disrupts the NR0B1 protein-protein interactions and impairs the anchorage-independent growth of KEAP1-mutant cancer cells.
-
NV03 is a potent and selective antagonist of UHRF1-H3K9me3 interaction by binding to UHRF1 TTD with a Kd of 2.4 μM and has anticancer activity.
-
sAJM589 is a Myc inhibitor which potently disrupts the Myc-Max heterodimer in a dose dependent manner with an IC50 of 1.8 μM.
-
Tasisulam is an anticancer agent and induces apoptosis, which also inhibits mitotic progression and induces vascular normalization.
-
IACS-8803 is a highly potent cyclic dinucleotide stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy.
-
S516 is a potent tubulin polymerization inhibitor with an IC50 of 4.29 μM and has marked antitumor activity against murine and human solid tumors.
-
CH6953755 is a potent, orally active and selective YES1 kinase inhibitor leading to antitumor activity against YES1 Gene -amplified cancers.
-
CA-4948 is a Selective and Orally Bioavailable IRAK4 Kinase Inhibitor for Lymphoma Treatment
2020-01-05
CA-4948 is a potent, selective and orally bioavailable IRAK4 kinase inhibitor. CA-4948 can be used for the treatment of lymphoma. -
ADH-503 is an orally active and allosteric CD11b agonist and leads to the repolarization of tumor-associated macrophages.
-
BI-9321 is a potent, selective and cellular active NSD3-PWWP1 domain antagonist, and specifically disrupts histone interactions of the NSD3-PWWP1 domain.
-
Balixafortide is a potent, selective peptidic CXCR4 antagonist with anti-cancer effects, and blocks β-arrestin recruitment and calcium flux.
-
SNDX-5613 is a potent, selective, small molecule inhibitor of the Menin-MLL binding interaction for targeted therapy in MLL-rearranged leukemias.
-
RBN-2397 is an orally active accross species NAD+ competitive inhibitor of PARP7. RBN-2397 binds to PARP7 and restores interferon (Type I) signaling.
-
MYCMI-6 is a selective MYC:MAX protein interactions inhibitor, which blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain.
-
TED-347 is a potent, irreversible, covalent and allosteric inhibitor at YAP-TEAD protein-protein interaction with antitumor activity.
-
GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor. GSK143 reduces inflammation in the intestinal muscularis in mice.
-
M-808 is a highly potent and efficacious covalent Menin-MLL interaction inhibitor. M-808 has a binding IC50 value of 2.6 nM.
-
MCP110 is an inhibitor of Ras/Raf-1 interaction in human cancer cells. The Ras family GTPases play a central role in the growth factor signaling.
-
ZZW-115, a NUPR1 Inhibitor, Possesses Anticancer Activity via Inducing Necroptosis and Apoptosis
2020-08-29
ZZW-115 is a potent NUPR1 inhibitor, with a Kd of 2.1 μM. ZZW-115 induces tumor cell death by necroptosis and apoptosis. ZZW-115 exerts anticancer activity. -
MSA-2 is an orally available non-nucleotide STING agonist. MSA-2 shows antitumor activity and stimulates interferon-β secretion in tumors.
-
CB-1158, a potent and orally bioavailable inhibitor of arginase, blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
-
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses effective anti-tumor activity in vitro and in vivo.
-
BC-LI-0186 is a selective inhibitor of LeuRS and RagD interaction (IC50=46.11 nM). BC-LI-0186 suppresses the activity of cancer-associated MTOR mutants.
-
GNE-371, a Chemical Probe for the Second Bromodomains of TFIID Subunit 1 and TFIID Subunit 1-Like
2020-12-09
GNE-371 is a selective chemical probe for the second bromodomains of human transcription-initiation-factor TFIID subunit 1 and TFIID subunit 1-like. -
WL47, a high-affinity cavolin-1 (CAV1) ligand (Kd=23 nM), act as a potent and selective disrupter of CAV1 oligomers.
-
G5-7, an orally active and allosteric JAK2 inhibitor. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect.
-
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM).
-
L-Moses is the first potent, selective, and cell-active PCAF Brd inhibitor. L-Moses disrupts PCAF-Brd histone H3.3 interaction.
-
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction. It induces high levels of IL-2.
-
MR837 is an Inhibitor of NSD2-PWWP1
2021-05-11
MR837 is a potent inhibitor of NSD2 (WHSC1)-PWWP1 protein-protein interaction. MR837 can bind with human NSD2. -
BI-3406 is a selective, orally bioavailable SOS1 inhibitor that binds to the catalytic domain of SOS1, preventing the interaction with KRAS.
-
PHT-7.3 is a Selective Inhibitor of Connector Enhancer of Kinase Suppressor of Ras 1 (Cnk1)
2021-05-27
PHT-7.3 is a selective inhibitor of Cnk1 pleckstrin homology (PH) domain. PHT 7.3 blocks the growth of mutant KRAS cells and tumors. -
Sitravatinib (MGCD516) is an Orally Bioavailable RTK Inhibitor with PD-1 Blockade Activity
2021-06-03
Sitravatinib, a small molecule RTK inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. -
NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor and inhibits SIX1-mediated breast cancer metastasis.
-
EMD527040 is a highly selective αvβ6 antagonist with antifibrotic activities.
-
Inupadenant is an orally active, highly selective A2A receptor antagonist with potent anti-tumor activity.
-
NRX-2663 is a potent enhancer of the interaction between β-catenin SCFβ-TrCP, potentiates the ubiquitylation of mutant β-Catenin by β-TrCP.
-
AZD4635 is a potent, selective and orally active antagonist of A2AR that reverses adenosine-mediated immune suppression.
-
CL097 is a TLR7/8 agonist. CL097 induces pro-nflammatory cytokines. CL097 induces NADPH oxidase priming and efficient diabetogenic cytotoxic T lymphocyte (CTL) function in NOD mice.
-
Indoximod, an immunometabolic adjuvant, is an orally active IDO pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR.
-
BM213 is a selective C5aR1 agonist. It’s a useful research tool to study C5aR1 function
-
Mirin is a potent MRN complex inhibitor. Mirin prevents MRN-dependent activation of ATM without affecting ATM protein kinase activity.
-
Gardiquimod is a TLR7/8 agonist and can inhibit HIV-1 infection.
-
Tiragolumab is an immune checkpoint inhibitor binding to TIGIT. Tiragolumab is effective against multiple solid malignancies.
-
MS159 is a frist-In-class nuclear receptor binding SET NSD2 PROTAC degrader for multiple myeloma research.
-
BSP16 is a potent, orally active stimulator of interferon genes (STING) agonist. BSP16 has potent anti-cancer activity.
-
CAM 833, a potent and selective inhibitor of the BRCA2-RAD51 interaction, and has the potential for the cancer research.
-
Serplulimab is a humanized monoclonal anti-PD-1 antibody and has the potential for the research of small cell lung cancer.
-
GN25 is a specific inhibitor of p53-Snail binding and shows anti-tumor effect against K-Ras-mutated cancer.
-
Mogamulizumab is an Anti-CCR4 monoclonal antibody. It enhances antibody-dependent cellular cytotoxicity and is effective against leukemia.
-
Bapotulimab (BAY-1905254) is an ILDR2 IgG antibody that blocks the immunosuppressive effects of ILDR2 on T-cell activation.
-
Nanrilkefusp alfa is a selective and strong IL-15 agonist. It inhibits tumor metastasis and viability by activating natural killer (NK) cells.
-
Urabrelimab (SRF231) is an anti-CD47 monoclonal antibody, blocking the CD47-SIRPα interaction. It has the potential to research anticancer.
-
Efineptakin alfa (NT-17) is a Long-Acting Recombinant Human IL-7 for Glioblastoma Research
2023-02-07
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa can be used for glioblastoma research. -
Tifcemalimab, a Humanized anti-BTLA monoclonal antibody, blocks the interaction of HVEM-BTLA by binding to BTLA and activates lymphocytes.
-
Geptanolimab (CBT-501) is a programmed death-1 (PD-1) monoclonal antibody. Geptanolimab can be used in research forsolid tumor research.
-
Dazostinag is a STING Agonist and Can be used for Antibody-Drug Conjugates (ADCs) Synthesis
2023-03-13
Dazostinag is a STING agonist and a playload, to synthesis antibody-drug conjugates (ADCs). It has antitumor activity in vivo.
Products
-
All
-
Inhibitors & Agonists
-
Isotope-Labeled Compounds
-
Fluorescent Dye
-
Peptides
-
Recombinant Proteins
-
Antibodies
-
Screening Libraries
-
Inhibitory Antibodies
-
Reference Standards
-
Induced Disease Models Products
-
GMP Small Molecules
-
Enzyme
-
Biochemical Assay Reagents
-
Natural Products
| Cat. No. | Product Name | Information | Application | Publication |
|---|---|---|---|---|
| HY-16658B | Z-VAD-FMK |
Z-VAD-FMK is a pan-caspase inhibitor and also an ICE-like protease inhibitor, which inhibits apoptosis by preventing the processing of CPP32 to its active form. Z-VAD-FMK sensitivity varies primarily due to differential expression of receptor-interacting protein 1 (RIP1). Z-VAD-FMK limits the cryopreservation-induced apoptosis by reducing caspase-3 activity of in vitro produced bovine embryos. Z-VAD-FMK is immunosuppressive in vitro and inhibits T cell proliferation without blocking the processing of caspase-8 and caspase-3. Z-VAD-FMK leads to a decrease in intracellular glutathione (GSH) with a concomitant increase in reactive oxygen species (ROS) levels in activated T cells. Z-VAD-FMK is due to oxidative stress via the depletion of GSH. Z-VAD-FMK can be used for the study of acute pancreatitis.
|
|
819
|
| HY-15760 | Necrostatin-1 |
Necrostatin-1 (Nec-1) is a potent and cross the blood-brain barrier necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. Necrostatin-1 inhibits RIP1 kinase (EC50=182 nM). Necrostatin-1 is also an IDO inhibitor.
|
|
561
|
| HY-12815A | MCC950 sodium |
MCC950 sodium (CP-456773 sodium; CRID3 sodium salt) is a potent, selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
|
|
486
|
| HY-12815 | MCC950 |
MCC950 (CP-456773; CRID3) is a potent and selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
|
|
486
|
| HY-100381 | Nigericin sodium salt |
Nigericin sodium salt is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin sodium salt is a NLRP3 activator. Nigericin sodium salt shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin sodium salt induces pyroptosis through caspase 1/GSDMD in TNBC.
Source: Streptomyces hygroscopicus |
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Ovarian Cancer
Bacterial Infection
Depression
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
249
|
| HY-127019 | Nigericin |
Nigericin is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin is a NLRP3 activator. Nigericin shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin induces pyroptosis through caspase 1/GSDMD in TNBC.
|
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Ovarian Cancer
Bacterial Infection
Depression
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
249
|
| HY-16658 | Z-VAD(OMe)-FMK |
|
207
|
|
| HY-112879 | Mito-TEMPO |
Mito-TEMPO is a mitochondria-targeted antioxidant. Mito-TEMPO induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. Mito-TEMPO regulates Ca2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. Mito-TEMPO reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. Mito-TEMPO can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke.
|
|
179
|
| HY-13205 | Belnacasan |
Belnacasan (VX-765) is an orally bioactive proagent of VRT-043198, which is a potent and selective inhibitor of IL-converting enzyme (ICE)/caspase-1 with Kis of 0.8 nM and less than 0.6 nM for caspase-1 and caspase-4, respectively. Belnacasan (VX-765) inhibits the release of LPS-induced IL-1β and IL-18 by human PBMCs with an IC50 of ~0.7 μM.
|
|
177
|
| HY-B2176B | ATP dimagnesium |
ATP (Adenosine 5'-triphosphate) dimagnesium is a central component of energy storage and metabolism in vivo. ATP dimagnesium provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP dimagnesium is an important endogenous signaling molecule in immunity and inflammation. ATP dimagnesium can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP dimagnesium has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
|
173
|
| HY-B2176A | ATP disodium trihydrate |
ATP (Adenosine 5'-triphosphate) disodium trihydrate is a central component of energy storage and metabolism in vivo. ATP disodium trihydrate provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP disodium trihydrate is an important endogenous signaling molecule in immunity and inflammation. ATP disodium trihydrate can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP disodium trihydrate has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
|
173
|
| HY-B2176 | ATP |
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
Source: widespread |
|
173
|
| HY-W010735 | ATP disodium salt hydrate |
ATP (Adenosine 5'-triphosphate) disodium salt hydrate is a central component of energy storage and metabolism in vivo. ATP disodium salt hydrate provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP disodium salt hydrate is an important endogenous signaling molecule in immunity and inflammation. ATP disodium salt hydrate can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP disodium salt hydrate has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
Source: widespread |
|
167
|
| HY-B2176C | ATP dipotassium |
ATP (Adenosine 5'-triphosphate) dipotassium is a central component of energy storage and metabolism in vivo. ATP dipotassium provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP dipotassium is an important endogenous signaling molecule in immunity and inflammation. ATP dipotassium can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP dipotassium has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
Source: widespread |
|
164
|
| HY-B2176I | ATP disodium salt, 100 mM Solution, PCR Grade |
ATP (Adenosine 5'-triphosphate) disodium salt, 100 mM Solution, PCR Grade is a central component of energy storage and metabolism in vivo. ATP disodium salt, 100 mM Solution, PCR Grade provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP disodium salt, 100 mM Solution, PCR Grade is an important endogenous signaling molecule in immunity and inflammation. ATP disodium salt, 100 mM Solution, PCR Grade can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP disodium salt, 100 mM Solution, PCR Grade has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
|
164
|
| HY-B0075 | Melatonin |
Melatonin is a hormone made by the pineal gland that can activate melatonin receptor and inhibit PANoptosis. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties. Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation. Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress.
|
Melatonin Receptor
Autophagy
Mitophagy
Endogenous Metabolite
Apoptosis
PANoptosis
Ligands for Target Protein for PROTAC
Histone Acetyltransferase
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Viral Infection
Neurodegenerative Disease
Digestive System Inflammation
SARS-CoV-2 Infection
|
145
|
| HY-100573 | Necrosulfonamide |
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
|
Mixed Lineage Kinase
Necroptosis
Pyroptosis
Caspase
NOD-like Receptor (NLR)
Keap1-Nrf2
TNF Receptor
Interleukin Related
NO Synthase
Heme Oxygenase (HO)
Digestive System Disease
Prostate Cancer
Leukemia/Lymphoma/Myeloma
Depression
Digestive System Inflammation
Cardiovascular Disease
Parkinson's Disease
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
144
|
| HY-12466 | Z-DEVD-FMK |
Z-DEVD-FMK is a specific and irreversible caspase-3 inhibitor with an IC50 of 18 μM.
|
|
138
|
| HY-12305 | Q-VD-OPh |
|
113
|
|
| HY-19696 | Tauroursodeoxycholate |
Colorectal Cancer
Prostate Cancer
Liver Cancer
Viral Infection
Neurodegenerative Disease
Pain
Digestive System Inflammation
Glucose Metabolism
Obesity
|
111
|
|
| HY-101872A | GSK-872 hydrochloride |
GSK-872 hydrochloride is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 hydrochloride decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury.
|
|
110
|
| HY-101872 | GSK-872 |
GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury.
|
|
110
|
| HY-L031 | Small Molecule Immuno-Oncology Compound Library |
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.
MCE Small Molecule Immuno-Oncology Compound Library offers 813 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.
|
|
88
|
| HY-L014 | NF-κB Signaling Compound Library |
Nuclear factor-κB (NF-κB)/Rel proteins include NF-κB2 p52/p100, NF-κB1 p50/p105, c-Rel, RelA/p65, and RelB. These proteins function as dimeric transcription factors that regulate the expression of genes and influence a broad range of biological processes including innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. NF-κB plays a key role in regulating the immune response to infection. In addition, activation of the NF-κB pathway is involved in the pathogenesis of chronic inflammatory diseases, such as asthma, rheumatoid arthritis, and inflammatory bowel disease. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development.
MCE owns a unique collection of 1,770 small molecule compounds that can be used in the research of NF-κB signaling pathway or high throughput screening (HTS) related drug discovery.
|
|
85
|
| HY-L059 | Pyroptosis Compound Library |
Programmed cell death pathways, including apoptosis, pyroptosis and necroptosis, are regulated by unique sets of host proteins that coordinate a variety of biological outcomes. Pyroptosis is a highly inflammatory form of programmed cell death that occurs most frequently upon infection with intracellular pathogens and is likely to form part of the antimicrobial response. This process promotes the rapid clearance of various bacterial, viral, fungal and protozoan infections by removing intracellular replication niches and enhancing the host's defensive responses. Pyroptosis has been widely studied in inflammatory and infection disease models. Recently, there are growing evidences that pyroptosis also plays an important role in the development of cancer, cardiovascular diseases and Metabolic disorder, etc.
MCE designs a unique collection of 1,985 pyroptosis-related compounds mainly focusing on the key targets in the pyroptosis signaling pathway and can be used in the research of pyroptosis signal pathway and related diseases.
|
|
84
|
| HY-L075 | Anti-Lung Cancer Compound Library |
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.
As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.
MCE offers a unique collection of 3,012 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.
|
|
84
|
| HY-L079 | Anti-Blood Cancer Compound Library |
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.
Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.
MCE offers a unique collection of 4,276 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.
|
|
83
|
| HY-L133 | Cuproptosis Compound Library |
Copper is an important co-factor of all biological enzymes, but if the concentration exceeds the threshold of maintaining the homeostasis mechanism, copper will lead to cytotoxicity. This death mechanism has been named "Cuproptosis".
The mechanism of cuproptosis distinct from all other known mechanisms of regulated cell death, including apoptosis, pyroptosis, necroptosis, and ferroptosis.
Copper combine with the lipoylated components of the tricarboxylic acid cycle (TCA), leading to lipoylated protein aggregation and subsequent loss of iron-sulfur cluster proteins, ultimately resulting in protein toxicity stress and cell death. Studies have shown that the necessary factors for cuproptosis include the presence of glutathione, mitochondrial metabolism of galactose and pyruvate, and glutamine metabolism.
Targeted regulation of cuproptosis is a potential choice to treat cancer, rheumatoid arthritis, and other diseases. For example, up-regulation of LIPT1 may inhibit the occurrence and development of tumors by destroying TCA in mitochondria and then inducing cuproptosis.
MCE supplies a unique collection of 440 cuproptosis-related compounds, all of which act on the targets or signaling pathways related to cuproptosis and may have in inhibitory or activated effect on cuproptosis. MCE Cuproptosis Library is a useful tool for drug research related to cancer, rheumatoid arthritis, and other diseases.
|
|
83
|
| HY-L156 | Autoimmune Disease Compound Library |
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).
MCE designs a unique collection of 1,021 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.
|
|
83
|
| HY-L161 | Cytokine Inhibitors Library |
Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases.
MCE designs a unique collection of 1,401 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.
|
|
83
|
| HY-L162 | Cell Death Library |
Cell death plays a crucial role in the development of the body and the maintenance of internal balance to prevent the development of diseases. According to the regulation of the involved processes, cell death can be defined as programmed and non-programmed death. Programmed cell death (PCD) can be divided into lytic cell death and nonlytic cell death, mainly including apoptosis, necrotic apoptosis and Pyroptosis. Non-Programmed cell death (Non-PCD) generally refers to necrosis. In stark contrast to Accidental Cell Death (ACD), Regulatory Cell Death (RCD) relies on specialized molecular mechanisms. Cell death includes internal apoptosis, external apoptosis, necrotic apoptosis, ferroptosis, pyroptosis, lysosome-dependent cell death, etc.
MCE designs a unique collection of 3,812 cell death compounds, covering multiple targets, such as Apoptosis, Ferroptosis, Pyroptosis, Necroptosis, etc. It is a useful tool for screening cell death drugs.
|
|
83
|
| HY-L162M | Cell Death Inhibitor Library Mini |
Cell death is a core biological process that maintains homeostasis in multicellular organisms, playing a dual role in life activities. On one hand, cell death participates in physiological processes such as cell renewal and damage repair through precise regulation; on the other hand, it actively eliminates damaged, infected, or cancerous cells, thereby blocking pathological progression and preserving organism health. Cell death not only ensures the normal development and growth regulation of organisms but is also closely associated with the occurrence and development of various diseases. Numerous studies have shown that specific types of programmed cell death play critical roles in disease progression, providing an important theoretical basis for developing novel therapeutic strategies by regulating cell death pathways.
MCE offers 23 types of commonly used cell death inhibitors, such as apoptosis, ferroptosis, pyroptosis, and cuproptosis, suitable for use as positive controls in the study of novel cell death mechanisms.
|
|
83
|
| HY-L174 | Macrophage Related Compound Library |
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance.
MCE designs a unique collection of 275 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.
|
|
83
|
| HY-L175 | Inflammasomes related Compound Library |
Inflammasomes are classic pattern recognition receptors for natural immune responses. Inflammasomes are polymeric protein complexes that regulate inflammatory responses and pyrolytic cell death, thereby exerting the host's defense against microorganisms. Inflammasomes sensors are associated with adapter proteins, activating inflammatory caspase-1, releasing inflammatory cytokines and inducing cell death, endowing the host with defense against pathogens. NLRP1, NLRP3, NLRC4, AIM2, and pyrin are considered typical inflammasomes because they convert cysteine asparaginase-1 into catalytically active capsaicin-1. In addition to infectious diseases, the importance of inflammasomes is also related to various clinical diseases, such as autoimmune diseases, neurodegeneration and metabolic disorders, and the development of cancer. Therefore, it is necessary to strictly regulate the activation and function of inflammasomes to avoid accidental host tissue damage while inducing pathogens to kill the inflammatory response.
MCE designs a unique collection of 176 inflammasomes related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.
|
|
83
|
| HY-L213 | Anti-Cancer Approved Drug Library |
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies.
This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment.
MCE has collected 268 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
|
|
83
|
| HY-L219 | Antimicrobial Peptides Library |
Antimicrobial Peptides (AMPs), also known as antimicrobial peptides or antibiotic peptides, are a class of polypeptides encoded by specific genes in various biological cells and induced by external stimuli. They exhibit broad-spectrum bioactivity against bacteria, fungi, viruses, protozoa, and even tumor cells. AMPs serve as crucial effector molecules in the host's innate immune system.Due to their wide antimicrobial spectrum, low toxicity to normal cells of higher animals, high safety profile, low tendency to induce resistance, and additional benefits such as immune enhancement and antioxidant effects, antimicrobial peptides hold significant promise in new drug development.
MCE offers 57 types of antimicrobial peptides, which can be applied in high-throughput screening for research in anti-infection therapies, immunotherapy, anticancer drug development, and agricultural disease control.
|
|
83
|
| HY-L237 | Pattern Recognition Receptors Library |
Pattern Recognition Receptors (PRRs) are a crucial class of protein molecules expressed in cells of the innate immune system. The core function of Pattern Recognition Receptors is to recognize Pathogen-Associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs). Upon recognizing and binding to PAMPs or DAMPs, PRRs rapidly initiate intracellular signaling pathways (such as the NF-κB, IRF, and inflammasome pathways). This triggers the production of inflammatory factors, chemokines, and type I interferons, thereby initiating inflammatory responses to eliminate pathogens or repair damage. PRRs represent the body's first line of defense against infection, and the rapidity and broad specificity of their response are crucial for host survival. However, aberrant activation of PRR signaling is also a cause of many chronic inflammatory diseases, autoimmune disorders, and neurodegenerative diseases. Therefore, precisely regulating PRR activity has become a key therapeutic strategy for these conditions.
MCE has cataloged 337 inhibitors targeting key PRRs, such as NLRs, TLRs, C-type Lectin Receptors (CLRs), and cGAS, to support drug discovery efforts for chronic inflammatory diseases.
|
|
83
|
| HY-L948 | PD-1/PD-L1 Lead-like Library |
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy.
A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity.
Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.
|
|
83
|
| HY-13755 | Sulforaphane |
Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties.
|
|
77
|
| HY-16569 | Colchicine |
Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research.
|
Digestive System Disease
Lung Cancer
Prostate Cancer
Viral Infection
Coronavirus Infection
Depression
Pain
Autoimmune Disease
Digestive System Inflammation
Alzheimer's Disease
Lung Fibrosis
|
73
|
| HY-135748 | Polyinosinic-polycytidylic acid sodium |
Polyinosinic-polycytidylic acid (Poly(I:C)) sodium is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis.
|
|
71
|
| HY-107202 | Polyinosinic-polycytidylic acid |
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
|
RIG-I-like receptor (RLR)
Toll-like Receptor (TLR)
PKD
HSP
Bcl-2 Family
Interleukin Related
Apoptosis
Infection
Digestive System Disease
Prostate Cancer
Pain
Digestive System Inflammation
Lung Fibrosis
Rheumatoid Arthritis
|
70
|
| HY-135748A | Poly (I:C):Kanamycin (1:1) sodium |
Poly (I:C):Kanamycin (1:1) sodium is an isometric complex of Poly (I:C) (HY-135748) and Kanamycin (HY-16566). Poly(I:C) sodium, a synthetic analog of double-stranded RNA, is a TLR3 and retinoic acid-inducible gene I receptor (RIG-I and MDA5) agonist. Poly(I:C) sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses and induce apoptosis in cancer cells. Kanamycin is an orally active antibacterial agent (Gram-negative/positive bacteria) that inhibits translocation and causes miscoding by binding to the 70S ribosomal subunit. Kanamycin shows good inhibitory activity against Mycobacterium tuberculosis (susceptible and drug-resistant) and Klebsiella pneumoniae, and can be used in the research of tuberculosis and pneumonia.
|
|
64
|
| HY-B1081A | Oxidopamine hydrobromide |
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome.
|
Dopamine Receptor
Autophagy
Mitophagy
COX
PGE synthase
Interleukin Related
p38 MAPK
Apoptosis
Caspase
|
49
|
| HY-12497 | ANA-12 |
ANA-12 is a brain-penetrant, selective TrkB antagonist with IC50 values of 45.6 nM and 41.1 μM, and Kd values of 10 nM and 12 μM, for high- and low-affinity sites, respectively. ANA-12 specifically inhibits BDNF-induced TrkB receptor activation and its downstream signaling cascades by directly and non-competitively binding to the TrkB receptor, without affecting the functions of TrkA and TrkC. ANA-12 is used in research concerning neuropsychiatric disorders (such as depression and anxiety), acute and chronic pain, neuroimmune inflammation, and the mechanisms of learning and memory.
|
|
39
|
| HY-14654 | Aspirin |
Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis.
|
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Neurodegenerative Disease
Depression
Pain
Digestive System Inflammation
Cardiovascular Disease
Non-Small Cell Lung Cancer
SARS-CoV-2 Infection
Obesity
Rheumatoid Arthritis
|
38
|
| HY-P9902 | Pembrolizumab |
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
Species: Human |
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
HER-2 Positive Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
35
|
| HY-14622A | Necrostatin 2 racemate |
Necrostatin 2 racemate (Nec-1S), the Necrostatin-1 (HY-15760) stable, is a potent and specific RIPK1 inhibitor lacking the IDO-targeting effect.
|
|
34
|
| HY-N0373 | Licochalcone B |
Licochalcone B is an extract from the root of Glycyrrhiza uralensis. Licochalcone B inhibits amyloid β (42) self-aggregation (IC50=2.16 μM) and disaggregate pre-formed Aβ42 fibrils, reduce metal-induced Aβ42 aggregation through chelating metal ionsLicochalcone B inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone B inhibits growth and induces apoptosis of NSCLC cells. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction.
|
Digestive System Disease
Lung Cancer
Depression
Autoimmune Disease
Digestive System Inflammation
Alzheimer's Disease
|
12
|
| HY-15594A | Phen-DC3 Trifluoromethanesulfonate |
Phen-DC3 Trifluoromethanesulfonate is a bisquinolinium G-quadruplex (G4) ligand. Phen-DC3 Trifluoromethanesulfonate selectively binds to and stabilizes the hybrid quadruplex-duplex hybrid (QDH) derived from the PIM1 promoter. Phen-DC3 Trifluoromethanesulfonate also binds to the c-myc promoter Pu24T G4 via extensive π-stacking, and induces polymerase stalling at α-synuclein DNA and RNA G4 sequences. Phen-DC3 Trifluoromethanesulfonate downregulates LPS (HY-D1056)-induced TNFRSF21, RIPK3 and p-MLKL in VECs, and ameliorates CLP-induced pulmonary vascular leakage in septic rats. Phen-DC3 Trifluoromethanesulfonate can be used in studies related to neurodegenerative diseases and sepsis-associated vascular injury.
|
|
12
|
| HY-107780A | Cyclic-di-GMP sodium |
Cyclic-di-GMP sodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP sodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP sodium can be used in cancer research.
Source: bacterial species |
|
9
|
| HY-107780 | Cyclic-di-GMP |
Cyclic-di-GMP is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP can be used in cancer research.
Source: bacterial species |
|
9
|
| HY-107780B | Cyclic-di-GMP diammonium |
Cyclic-di-GMP diammonium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP diammonium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP diammonium can be used in cancer research.
|
|
9
|
| HY-100339 | GSK583 |
GSK583 is a highly potent, orally active and selective inhibitor of RIP2 Kinase, with IC50 of 5 nM. GSK583 inhibits both TNF-α and IL-6 production with an IC50 value of 200 nM.
|
|
9
|
| HY-110382 | Cyclic-di-GMP disodium |
Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research.
|
|
9
|
| HY-P3211 | Nangibotide |
Nangibotide (LR12) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide inhibits Apoptosis. Nangibotide reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Autoimmune Disease
Digestive System Inflammation
Cardiovascular Disease
Obesity
|
8
|
| HY-P3211A | Nangibotide TFA |
Nangibotide TFA (LR12 TFA) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide TFA inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide TFA inhibits Apoptosis. Nangibotide TFA reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide TFA can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure.
|
|
8
|
| HY-107202A | Poly (I:C):Kanamycin (1:1) |
Poly(I:C):Kanamycin (1:1) is a mixture of Poly(I:C) (HY-107202) and Kanamycin (HY-16566). Poly(I:C) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Poly(I:C) can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Poly(I:C) can directly trigger cancer cells to undergo apoptosis. Kanamycin stabilizes Poly(I:C).
|
Toll-like Receptor (TLR)
RIG-I-like receptor (RLR)
PKD
HSP
Bcl-2 Family
Interleukin Related
Apoptosis
Infection
Digestive System Disease
Prostate Cancer
Pain
Digestive System Inflammation
Rheumatoid Arthritis
|
8
|
| HY-P1934 | Cyclo(Phe-Pro) |
Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) is a quorum-sensing molecule of Vibrio vulnificus that specifically interacts with RIG-I, inhibiting RIG-I polyubiquitination, suppressing IRF-3 activation, and reducing type I interferon production. Cyclo(Phe-Pro) enhances susceptibility to HCV and influenza virus and also alleviates plant aluminum toxicity stress. The mechanism of Cyclo(Phe-Pro) involves the regulation of host immune signaling pathways, bacterial virulence gene expression, and plant antioxidant systems, making it a promising candidate for research in viral infections, bacterial virulence regulation, and agricultural stress resistance.
|
|
7
|
| HY-144828 | RIP1/RIP3/MLKL activator 1 |
RIP1/RIP3/MLKL activator 1 (Compound 6i) is a potent anti-glioma agent. RIP1/RIP3/MLKL activator 1 induces necroptosis through RIP1/RIP3/MLKL pathway. RIP1/RIP3/MLKL activator 1 exerts acceptable BBB permeability.
|
|
7
|
| HY-B1521 | Aluminum Hydroxide |
Aluminum Hydroxide is an orally active main form of aluminum used as adjuvant. Aluminum hydroxide-based adjuvant researches include the repository effect, pro-phagocytic effect, and activation of the pro-inflammatory NLRP3 pathway. Aluminum Hydroxide also acts as adjuvant to compensate low inherent immunogenicity of subunit vaccines.
|
|
7
|
| HY-N0417 | Cucurbitacin E |
Cucurbitacin E is a CDK1 inhibitor that significantly inhibits the activity of the cyclin B1/CDC2 complex. Cucurbitacin E also induces PANoptosis in adrenocortical carcinoma cells in a ZBP1-dependent manner. Cucurbitacin E exhibits synergistic effects with Mitotane (HY-13690); when used in combination, they effectively eliminate tumors.
|
Breast Cancer
Leukemia/Lymphoma/Myeloma
Ovarian Cancer
Glucose Metabolism
Experimental Autoimmune Encephalomyelitis
Experimental Autoimmune Encephalomyelitis
|
6
|
| HY-N0816 | Polyphyllin VI |
Polyphyllin VI, an active saponin, possess anti-cancer activities. Polyphyllin VI induces G2/M cell cycle arrest and triggers apoptosis. Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS/NF-κB/NLRP3/GSDMD signal axis in non-small cell lung cancer.
|
|
6
|
| HY-P99032 | Monalizumab |
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
Species: Human |
|
5
|
| HY-N6712 | Thiolutin |
Thiolutin (Acetopyrrothin) is a sulfur-containing antibiotic, which is a potent inhibitor of bacterial and yeast RNA polymerases. Thiolutin can be produced by Streptomyces. Thiolutin inhibits AMSH (IC50 = 4 μM) and Rpn11 (IC50 = 0.53 μM). Thiolutin is a dual inhibitor of BRCC36 and the NLRP3 inflammasome, exhibiting anti-inflammatory effects. Thiolutin effectively suppresses the interaction between BRCC36 and HMGCR, leading to the inhibition of HCC growth. Thiolutin attenuates pyroptosis and NLRP3 inflammasome activation. Thiolutin markedly alleviates renal injury and inflammatory process in IgAN. Thiolutin is an anti-angiogenic compound which can ease Doxorubicin-induced cardiotoxicity (DOXIC).
Source: Streptomyces |
Antibiotic
Bacterial
Deubiquitinase
NOD-like Receptor (NLR)
DNA/RNA Synthesis
Pyroptosis
HMG-CoA Reductase (HMGCR)
|
4
|
| HY-D0014 | Brilliant blue G-250 |
Brilliant Blue G-250 is a dye commonly used for the visualization of proteins separated by SDS-PAGE, offering a simple staining procedure and high quantitation. In the Bradford protein assay, protein concentrations are determined by the absorbance at 595 nm due to the binding of Brilliant Blue G-250 to proteins. Brilliant Blue G-250 is a safe highly selective P2×7R antagonist with promising consequent inactivation of NLRP3 inflammasome.
|
|
4
|
| HY-N0633 | Muscone |
Environmental Pollutants
NF-κB
P-glycoprotein
Interleukin Related
TNF Receptor
NOD-like Receptor (NLR)
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Cardiovascular Disease
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
4
|
|
| HY-B2123 | Lactose |
Lactose is a β-galactoside consisting of galactose and glucose residues, the main carbohydrate in mammalian breast milk. Lactose, a macronutrient and an inducer of host innate immune responses, possesses immune modulatory functions.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
SARS-CoV-2 Infection
Obesity
|
4
|
| HY-N1431 | Tabersonine |
Tabersonine is a selective, orally active NLRP3 inhibitor. Tabersonine directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer.
|
NOD-like Receptor (NLR)
NF-κB
CDK
p38 MAPK
Cytochrome P450
Akt
Interleukin Related
Apoptosis
PI3K
Caspase
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Neurodegenerative Disease
Depression
Pain
Digestive System Inflammation
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
3
|
| HY-32350 | Ercalcitriol |
Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases.
|
|
3
|
| HY-N0639 | Punicalin |
Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonic anhydrase inhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity.
|
|
3
|
| HY-126741 | Azadirachtin |
Azadirachtin is an oral active triterpenoid compound with anticancer, antimalarial, anti-inflammatory, and insecticidal activities. Azadirachtin induces cell apoptosis through the mitochondrial pathway (by inhibiting Bcl-2/Bax ratio or activating Apaf-1 and caspase-3) or through death receptors (by inhibiting TNFR activation). Additionally, Azadirachtin exerts its anti-inflammatory effects by inhibiting NF-кB signaling pathway activation, and it exhibits insecticidal activity by inducing apoptosis in insect cells.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Parasitic Infection
Depression
Pain
Digestive System Inflammation
Obesity
|
3
|
| HY-P3434 | Ac-FEID-CMK |
Ac-FEID-CMK is a potent zebrafish-specific GSDMEb-derived peptide inhibitor.
Ac-FEID-CMK can attenuate the mortality and kidney injury during septic shock. Ac-FEID-CMK inhibits pyroptosis and attenuates septic AKI (acute kidney injury) in vivo. Ac-FEID-CMK can suppress the caspy2-mediated noncanonical inflammasome pathway.
|
|
2
|
| HY-P3434A | Ac-FEID-CMK TFA |
Ac-FEID-CMK TFA is a potent zebrafish-specific GSDMEb-derived peptide inhibitor.
Ac-FEID-CMK TFA can attenuate the mortality and kidney injury during septic shock. Ac-FEID-CMK TFA inhibits pyroptosis and attenuates septic AKI (acute kidney injury) in vivo. Ac-FEID-CMK TFA can suppress the caspy2-mediated noncanonical inflammasome pathway.
|
|
2
|
| HY-N0546 | Ligustroflavone |
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Colorectal Cancer
Prostate Cancer
Cardiovascular Disease
Glucose Metabolism
Obesity
Lung Fibrosis
|
2
|
| HY-19961 | KIN1408 |
KIN1408 is an agonist of the RIG-1-like receptor (RLR) pathway and exhibits a broad-spectrum antiviral activity. KIN1408 exhibits activity against HCV, influenza A, dengue virus 2, Ebola, Nipah, and Lassa viruses.
|
|
2
|
| HY-N1990 | Gypenoside XLIX |
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a Ka value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-α agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation.
|
PPAR
Sirtuin
Keap1-Nrf2
Toll-like Receptor (TLR)
NF-κB
Reactive Oxygen Species (ROS)
NOD-like Receptor (NLR)
Apoptosis
Pyroptosis
Autophagy
Neurological, Eye or Ear Disease
Atherosclerosis and Inflammation
Acute Lung Injury
Cardiomyopathy
Liver Injury
|
2
|
| HY-B0339 | Primidone |
Primidone is the orally active inhibitor for TRPM3 (IC50 = 0.6 μM), RIP kinase and voltage-gated sodium channel, and the antagonist for GABA receptor. Primidone can be used as the analgesic and anticonvulsant agent.
|
Digestive System Disease
Pain
Digestive System Inflammation
SARS-CoV-2 Infection
Alzheimer's Disease
Parkinson's Disease
|
2
|
| HY-119109 | Laminaran |
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.
Source: Eisenia Bicyclis |
|
2
|
| HY-125859 | Peroxidase, Horseradish |
Peroxidase, Horseradish actively involves in oxidizing reactive oxygen species, innate immunity, hormone biosynthesis and pathogenesis of several diseases.
|
|
2
|
| HY-P86158 | Cleaved N-terminal GSDMD Antibody (YA5850) |
Cleaved N-terminal GSDMD Antibody (YA5850) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cleaved N-terminal GSDMD. GSDMD exists in multiple protein isoforms: the ~53 kDa GSDMD precursor, the ~35 kDa cleaved GSDMD-N fragment, and the ~22 kDa cleaved GSDMD-C fragment. This antibody specifically detects the ~35 kDa GSDMD-N fragment produced following GSDMD cleavage at Asp275.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
2
|
| HY-P85810 | GSDMD (N-terminal) Antibody (YA5502) |
GSDMD (N-terminal) Antibody (YA5502) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to GSDMD.
Host: Mouse; Reactivity: Human, Mouse, Rat |
|
2
|
| HY-P83706 | GSDMD Antibody (YA3443) |
GSDMD Antibody (YA3443) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GSDMD.
Host: Rabbit; Reactivity: Human |
|
2
|
| HY-141567 | Pseudouridine 5'-triphosphate |
Pseudouridine 5'-triphosphate (Pseudo-UTP) is a modified ribonucleoside triphosphate and uracil base-modified UTP derivative. Pseudouridine 5'-triphosphate enhances translational properties and stability of mRNA, reduces innate immune responses in mammalian cells, and inhibits signal-dependent transcription termination of vaccinia virus early gene transcription while supporting transcription elongation. Pseudouridine 5'-triphosphate can be used for the research of vaccinia virus infection.
|
|
1
|
| HY-B0298AS | Clemastine-d5 fumarate |
Clemastine (HS-592; Meclastine)-d5 fumarate is the deuterium labeled Clemastine fumarate. Clemastine fumarate is an orally active, blood-brain barrier-permeable H1 histamine receptor (H1 histamine receptor) antagonist with potent antiallergic effects. Clemastine fumarate also antagonizes muscarinic acetylcholine receptors (mAChR), particularly the M1 and M4 subtypes. In addition to antihistamine effects, Clemastine fumarate exhibits multiple pharmacological activities, especially in promoting central nervous system remyelination, activating autophagy and pyroptosis, exerting anti-apoptotic and neuroprotective effects, and suppressing inflammation .
|
Isotope-Labeled Compounds
mAChR
p62
IKK
Apoptosis
Keap1-Nrf2
mTOR
Histamine Receptor
Pyroptosis
Autophagy
|
1
|
| HY-N6689 | Destruxin A |
Destruxin A is a fungal cyclopeptide with insecticidal and antiviral activities. Destruxin A has a certain inhibitory effect on leukemia cells in vitro. Destruxin A can also specifically inhibit the innate immune response of Drosophila melanogaster, making the flies more susceptible to bacterial infections.
Source: Metarhizium anisopliae |
|
1
|
| HY-P3496 | Pep19-2.5 |
Pep19-2.5 is an synthetic and antitoxin peptide, blocks the intracellular endotoxin signaling cascade. Pep19-2.5 inhibits signaling of lipopeptides (LP) and lipopolysaccharides (LPS) mediated by transmembrane and cytosolic pattern recognition receptors (PRRs). The signaling cascades lead to inflammation and cell pyroptosis.
|
|
1
|
| HY-N5084 | Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside |
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside blocks TRPV1-mediated calcium influx, suppresses phosphorylation of p65, IκBα, p38, JNK, and ERK1/2, inhibiting NF-κB and MAPK signaling cascades. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside reduces production and gene expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside exhibits potent analgesic activity, elevates thermal pain threshold and mechanical pain threshold in murine models. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside restores CD8+ T cell infiltration into bladder cancer tumors and improves bladder cancer immunotherapy efficacy. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside can be used for the researches of painand bladder cancer.
|
|
1
|
| HY-N8572 | 3',4'-Dimethoxyflavone |
3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of PARP and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Breast Cancer
Pancreatic Cancer
Ovarian Cancer
Cardiovascular Disease
|
1
|
| HY-B2176S5 | ATP-15N5 dilithium |
ATP-15N5 (Adenosine 5'-triphosphate-ATP-15N5) dilithium is the 15N5-labeled ATP (HY-B2176). ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
Isotope-Labeled Compounds
Endogenous Metabolite
NOD-like Receptor (NLR)
Interleukin Related
Bacterial
|
1
|
| HY-141567A | Pseudouridine 5'-triphosphate trisodium solution (100 mM) |
Pseudouridine 5'-triphosphate (Pseudo-UTP) trisodium solution (100 mM) is a modified ribonucleoside triphosphate and uracil base-modified UTP derivative. Pseudouridine 5'-triphosphate trisodium solution (100 mM) enhances translational properties and stability of mRNA, reduces innate immune responses in mammalian cells, and inhibits signal-dependent transcription termination of vaccinia virus early gene transcription while supporting transcription elongation. Pseudouridine 5'-triphosphate trisodium solution (100 mM) can be used for the research of vaccinia virus infection.
|
|
1
|
| HY-P9928A | Alirocumab (anti-PCSK9) |
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation.
Species: Human |
|
1
|
| HY-P99044 | Sabatolimab |
|
1
|
|
| HY-P1137 | 10Panx |
10Panx is a competitive inhibitor of selective Pannexin 1 (PANX1) channels. 10Panx blocks the opening of PANX1 channels, inhibits ATP release and downstream P2X7 receptor-mediated signaling pathways, thereby reducing cell death and inflammatory responses. 10Panx can be used in the study of diseases such as neuropathic pain, inflammatory bowel disease, and Clostridioides difficile infection. 10Panx can effectively reduce mechanical hyperalgesia and enhanced C-reflexes, and inhibit the expression of pro-inflammatory factors such as IL-6[1][2][3].
|
|
1
|
| HY-W041892 | Dimethyl itaconate |
Dimethyl itaconate induces innate immune memory (trained immunity), and exhibits immunomodulatory property. Dimethyl itaconate inhibits the activation of microglia, reduces the neuroinflammation and synaptic structural damage. Dimethyl itaconate regulates the composition of intestinal flora.
|
|
1
|
| HY-N2397 | 9''-Methyl salvianolate B |
9''-Methyl salvianolate B (MSB) is a blood-brain barrier-permeable inhibitor with high affinity for g5Rp, with a Kd value of 117 nM against African swine fever virus (ASFV) g5Rp. 9''-Methyl salvianolate B also acts as a ZBP1 inhibitor. It exhibits strong binding affinity to key proteins in the PPARγ/NF-κB pathway. 9''-Methyl salvianolate B blocks the interaction between ASFV g5Rp and host proteins eIF5A or RPS15. It restores hypusination modification of eIF5A, promotes autophagy (Autophagy), and inhibits ASFV replication. 9''-Methyl salvianolate B effectively disrupts ZBP1-mediated PANoptosome assembly. It effectively alleviates myocardial ischemia/reperfusion injury. 9''-Methyl salvianolate B can be used in studies related to African swine fever.
|
|
1
|
| HY-P9928 | Alirocumab |
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation.
Species: Human |
|
1
|
| HY-P11289 | Intermedin1-53 (Human) |
Intermedin1-53 (Human) is a 53-aa human calcitonin family peptide that reduces the vulnerability of atherosclerotic plaques by inhibiting CHOP-mediated macrophage apoptosis and inflammasome.
|
|
/
|
| HY-150659S | ATP-d14 disodium |
ATP-d14 (Adenosine 5'-triphosphate-ATP-d14) sodium is the d14-labeled ATP (HY-B2176). ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
|
/
|
| HY-N0660R | Jujuboside B (Standard) |
Jujuboside B (Standard) is the analytical standard of Jujuboside B. This product is intended for research and analytical applications. Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway. Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.
|
Reference Standards
ERK
p38 MAPK
Akt
PI3K
11β-HSD
STING
VEGFR
Ferroptosis
Autophagy
Apoptosis
Keap1-Nrf2
Caspase
PARP
AMPK
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
Colorectal Cancer
Leukemia/Lymphoma/Myeloma
Depression
Non-Small Cell Lung Cancer
|
/
|
| HY-P2617 | Ac-WEHD-AFC |
|
/
|
|
| HY-138071 | 8α-Tigloyloxyhirsutinolide 13-O-acetate |
8α-Tigloyloxyhirsutinolide 13-O-acetate (8αTGH) is a potent and orally active STAT3 inhibitor. 8α-Tigloyloxyhirsutinolide 13-O-acetate induces early oxidative stress and pyroptosis, and late DNA damage, cell cycle arrest, apoptosis in the TNBC cells. 8α-Tigloyloxyhirsutinolide 13-O-acetate suppresses tumor cell growth in vitro and tumor growth in vivo.
|
|
/
|
| HY-P11607 | CyLip-10 |
CyLip-10 is a microbial-derived cyclic-lipid antimicrobial peptide. CyLip-10 has broad-spectrum antimicrobial efficacy, low hemolytic activity, and excellent stability. CyLip-10 can disrupt membrane integrity, inhibit biofilm formation and induce membrane permeabilization and bacterial cell death. CyLip-10 reduces bacterial load, promotes wound healing, and alleviates inflammatory responses in a mouse Methicillin (HY-121544)-resistant Staphylococcus aureus skin wound infection model. CyLip-10 can be used for the bacterial infection.
|
|
/
|
| HY-154921A | Lactosylceramide (porcine RBC) |
Lactosylceramide (LacCer) (porcine RBC) is an endogenous bioactive sphingolipid. Lactosylceramide (porcine RBC) plays a pivotal role in mediating innate immune functions.
|
|
/
|
| HY-P1934AR | Cyclo(L-Phe-L-Pro) (Standard) |
Gallic acid (hydrate) (Standard) is the analytical standard of Gallic acid (hydrate). This product is intended for research and analytical applications. Cyclo(L-Phe-L-Pro), isolated from Pseudomonas fluorescens and Pseudomonas alcaligenes cell-free culture supernatants is an antifungal cyclic dipeptide. Cyclo(L-Phe-L-Pro) inhibits IFN-β production by interfering with retinoic-acid-inducible gene-I (RIG-I) activation. Cyclo(L-Phe-L-Pro) exhibits free-radical scavenging activity with the IC50 of 24 µM in the DPPH assay.
|
|
/
|
| HY-W013403S | 2'-Deoxy-2'-fluorouridine-d2 |
2'-Deoxy-2'-fluorouridine-d2 is the deuterium labeled 2'-Deoxy-2'-fluorouridine. 2'-Deoxy-2'-fluorouridine is a derivative of the pyrimidine nucleoside uridine. 2'-Deoxy-2'-fluorouridine is a nucleoside analog that inhibits the replication of wild-type viruses by binding to the viral RNA. Hepatitis C polyU/UC RNA strands containing 2'-Deoxy-2'-fluorouridine, bind to RIG-I but do not activate RIG-I signaling in a reporter assay using Huh7 cells. 2'-Deoxy-2'-fluorouridine also has been used as a starting material in the synthesis of respiratory syncytial virus (RSV) polymerase inhibitors. 2'-Deoxy-2'-fluorouridine can incorporate into DNA and RNA in rat and woodchuck model upon administration. 2'-Deoxy-2'-fluorouridine can be studied in anti-viral research.
|
|
/
|
| HY-P10939 | Ac-DMLD-CMK |
Ac-DmLD-CMK is a caspase 3 inhibitor and a GSDME inhibitor. Ac-DmLD-CMK binds directly to the catalytic domain of caspase-3, blocks caspase-3-mediated cleavage of GSDME, inhibits the activation of caspase 3 and Gsdme in the caspase 3-Gsdme signaling pathway, and reduces the levels of pyroptosis and apoptosis as well as the expression of LDH, IL-6, IL-1β and IL-18. Ac-DmLD-CMK alleviates renal function deterioration, renal tubular epithelial cell injury, inflammatory cytokine secretion, pulmonary structural damage, and chemotherapy-induced nephrotoxicity.
|
|
/
|
| HY-P11580 | Pap12-6-10 |
Pap12-6-10 is an MD-2 ligand that binds to the hydrophobic pocket of MD-2 to inhibit the dimerization of the TLR4/MD-2 complex and downstream inflammatory signal transduction. Pap12-6-10 also binds to LPS to permeabilize bacterial cell membranes and induce oxidative stress, leading to bacterial death. Pap12-6-10 regulates LPS-induced inflammatory responses through the TLR4 signaling pathway and exhibits antibacterial activity against multidrug-resistant Gram-negative bacteria. Pap12-6-10 shows low tendency to induce drug resistance and low preclinical cytotoxicity, and it prevents organ damage in a mouse model of sepsis. Pap12-6-10 can be used for research related to Gram-negative sepsis and carbapenem-resistant Acinetobacter baumannii infections.
|
|
/
|
| HY-N0816R | Polyphyllin VI (Standard) |
Polyphyllin VI (Standard) is the analytical standard of Polyphyllin VI. This product is intended for research and analytical applications. Polyphyllin VI, an active saponin, possess anti-cancer activities. Polyphyllin VI induces G2/M cell cycle arrest and triggers apoptosis. Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS/NF-κB/NLRP3/GSDMD signal axis in non-small cell lung cancer.
|
|
/
|
| HY-P991305 | AGEN-1571 |
|
/
|
|
| HY-P5169 | LVGRQLEEFL (mouse) |
LVGRQLEEFL (mouse) can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death.
|
|
/
|
| HY-P2291 | Beta-defensin 103 isoform X1, pig |
Beta-defensin 103 isoform X1, pig is an antimicrobial peptide found in different living organisms, involved in the first line of defense in their innate immune response against pathogens.
|
|
/
|
| HY-P10978 | NK224 |
NK224 is a peptide-based radiotracer targeting human PD-L1, with dual-radionuclide (68Ga and 18F) labeling compatibility enabled by the NOTA chelator. NK224 exhibits high binding affinity to PD-L1, with an IC50 value of 2.45 nM. NK224 visualizes intrapatient tumor heterogeneity and dynamically monitors PD-L1 target occupancy during immunotherapy. NK224 can be used for the study of non-small cell lung cancer (NSCLC).
|
|
/
|
| HY-P992382 | IC 100 |
IC 100 is a humanized IgG4κ monoclonal antibody targeting apoptosis-associated speck-like protein (ASC) with blood-brain barrier permeability. IC 100 specifically inhibits ASC after being endocytosed via its Fc segment, blocks ASC polymerization and inflammasome activation, suppresses IL-1β release, forms complexes with ASC and TRIM21, and evades TRIM21-mediated proteasomal degradation. IC 100 alleviates symptoms associated with autoimmune encephalomyelitis, reduces immune cell infiltration and microglial activation in the mouse EAE model. IC 100 is suitable for research on neuroinflammatory and inflammasome-related diseases such as multiple sclerosis. Isotype comparison: HY-P99003.
Species: Human |
|
/
|
| HY-N15380 | 4,4′-Secalonic acid D |
4,4′-Secalonic acid D (Compound 12) is a PARP1 inhibitor. 4,4′-Secalonic acid D induces the accumulation of ROS and DNA damage, activates the caspase-3/GSDME pathway, and triggers apoptosis and pyroptosis of tumor cells by inhibiting PARP1. 4,4′-Secalonic acid D has anti-tumor activity.
Source: Paraconiothyrium sp. |
|
/
|
| HY-P10656 | Ac-DEVDD-TPP |
Ac-DEVDD-TPP is a porphyrin derivative that can be converted into D-TPP by caspase-3 cleavage and laser irradiation. The formed porphyrin nanofibers can effectively induce Apoptosis and Pyroptosis. Ac-DEVDD-TPP has antitumor activity.
|
|
/
|
| HY-N0891R | Tubeimoside II (Standard) |
Tubeimoside II (Standard) (Tubeimoside-B (Standard)) is the analytical standard of Tubeimoside II (HY-N0891). This product is intended for research and analytical applications. Tubeimoside II is an orally active triterpenoid saponin and antiviral agent that binds to PACT/PRKRA with Kd values of 5.37 μM and 133.1 μM, respectively. Tubeimoside II inhibits oxidase-dependent EGFR activation and reduces TGF-β1-induced oxidative stress. Tubeimoside II activates the RIG-I signaling pathway and increases IFN-β secretion. Tubeimoside II suppresses TPA-induced ear edema, mouse sarcoma 180 growth, and TPA-induced skin tumor formation. Tubeimoside II exerts broad-spectrum antiviral activity against SARS-CoV-2, HCoV-OC43, and IAV-H1N1/FM1. Tubeimoside II can be used in research related to retinoblastoma, respiratory viral infections, skin tumors, and sarcoma 180.
|
|
/
|
| HY-P1813 | PSA1 (141-150) |
PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments.
|
|
/
|
| HY-P992518 | Pumitamig (Mouse IgG2a) |
Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
|
|
/
|
| HY-P11581 | MNP2 |
MNP2 is a NLRP3-ASC interaction inhibitor. MNP2 selectively binds to the PYD domain of ASC (Ka=149 nM) and blocks ASC-PYM binding (Ka=58 nM), thereby inhibiting the interaction between ASC and NLRP3 and suppressing the formation of the NLRP3 inflammasome. MNP2 inhibits IL-1β release and caspase-1 maturation, and reduces the efflux of potassium and chloride ions. MNP2 prevents mitochondrial damage and reactive oxygen species production, and significantly decreases NLRP3 inflammasome formation in neurodegenerative pathologies induced by β-amyloid, Tau protein and α-synuclein. MNP2 is applicable for the research of neurodegenerative diseases.
|
|
/
|
| HY-P992051 | Anti-CD103 Antibody (hCD103.01A) |
Anti-CD103 Antibody (hCD103.01A) is a monoclonal antibody targeting human CD103 and can be used in cancer immunotherapy and immunological research. Recommend Isotype Controls: human IgG1 kappa, Isotype Control (HY-P99001).
Species: Human |
|
/
|
| HY-126675G | AS2863619 (GMP) |
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4+ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects.
|
|
/
|
| HY-147338S2 | 5-Methylcytidine 5′-triphosphate-d8 trisodium |
5-Methylcytidine 5'-triphosphate-d8 trisodium is the deuterium-labeled form of 5-Methylcytidine 5'-triphosphate trisodium (HY-147338A). 5-Methylcytidine 5'-triphosphate (5-Methyl-CTP) trisodium is a modified nucleoside triphosphate. 5-Methylcytidine 5'-triphosphate trisodium can be used to replace unmodified mRNA, resulting in the increase of translational properties and stability, as well as the reduction of innate immune responses in human and other mammalian cells.
|
|
/
|
| HY-B0621S | Triclabendazole-d3 |
Triclabendazole-d3 is the deuterium labeled Triclabendazole (HY-B0621). Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica.
|
|
/
|
| HY-W007328S | 5-Methoxyindole-d3 |
5-Methoxyindole-d3 is the deuterated-labeled 5-Methoxyindole (HY-W007328). 5-Methoxyindole is an L-tryptophan metabolite with antifungal activity, and also serves as a pharmaceutical intermediate. Metabolites of 5-Methoxyindole exhibit COX-2 inhibitory, anti-inflammatory and anti-tumor activities. 5-Methoxyindole induces morphological distortion of hyphae and conidia, ROS accumulation, apoptosis and cell death in Gaeumannomyces graminis. 5-Methoxyindole can be used in studies related to fungal infections and organic synthesis.
|
Isotope-Labeled Compounds
Endogenous Metabolite
Drug Intermediate
Fungal
Reactive Oxygen Species (ROS)
Apoptosis
|
/
|
| HY-P991634 | IBI-325 |
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.
Species: Human |
|
/
|
| HY-N20662 | (+)-Neoalbaconol |
(+)-Neoalbaconol is a selective Akt/PDK1 inhibitor (with an IC50 of 10 μM against hPDK1). (+)-Neoalbaconol selectively inhibits cancer cell proliferation, and induces energy depletion, apoptosis, autophagy and necroptosis in cancer cells. In addition, (+)-Neoalbaconol downregulates cIAP1/2 and TRAFs to activate non-canonical NF-κB and promote TNFα transcription, blocks EGFR-mediated VEGF production and receptor activation, and mediates cell necrosis via the RIPK3-ROS-dependent pathway. (+)-Neoalbaconol can be used in research related to nasopharyngeal carcinoma, melanoma, breast cancer and gastric cancer.
Source: Dictyopteris divaricata Okam |
|
/
|
| HY-P10400 | AtPep1 |
AtPep1 is an endogenous inducer of innate immune responses. AtPep1 can be isolated from Arabidopsis thaliana leaves. AtPep1 activates the transcription of defensin (PDF1.2), the expression of PROPEP1, the synthesis of hydrogen peroxide (H2O2) near leaf veins, and the alkalization of Arabidopsis suspension cell culture medium. AtPep1 induces the expression of genes encoding defensins and PR-1. AtPep1 is applicable to studies related to Pythium irregulare infection and pathogen infection.
|
|
/
|
| HY-P5640 | Tritrpticin |
Tritrpticin is a porcine-derived antimicrobial peptide with properties such as membrane disruption and hemolysis. Tritrpticin disrupts the cell membranes of bacteria, fungi and Jurkat T cell leukemia cells and induces their death. Tritrpticin also enhances the efficacy of Metronidazole (HY-B0318) against *Trichomonas vaginalis*, reduces plasma endotoxin and inflammatory cytokine levels, restricts bacterial growth in blood and visceral tissues, decreases the mortality rate of septic shock in rats and enhances the therapeutic effect of ertapenem. Tritrpticin exhibits selective cytotoxicity against Jurkat T cell leukemia cells, while showing low toxicity to normal peripheral blood mononuclear cells and red blood cells, and can serve as a template for antimicrobial peptide design. Tritrpticin can be applied to research related to bacterial infections, fungal infections, trichomoniasis, septic shock and leukemia.
|
|
/
|
| HY-W724344 | Cetalkonium-d5 chloride |
Cetalkonium-d5 chloride (Benzyldimethylhexadecylammonium-d5 chloride) is the deuterium labeled Cetalkonium chloride (HY-B1597). Cetalkonium chloride is an ammonium antiseptic agent used in many topical agents for infections of mouth, throat and eye. Cetalkonium chloride acts as anti-inflammatory amphiphilic agent. Cetalkonium chloride is a cationic surfactant, that improves the precorneal residence time and bioavailability of drugs. Cetalkonium chloride interacts with the negative charges on the bacterial cell membrane, disrupts the integrity of the cell membrane, causes leakage of cell contents and ultimately leading to bacterial death.
|
|
/
|
| HY-P11935 | RR-171 |
RR-171 is an amino acid polypeptide and an inhibitor of the Wnt signaling pathway. RR-171 reduces the expression levels of Wnt-1, GSK3β and β-catenin. RR-171 induces apoptosis (Apoptosis) in pancreatic cancer cells, which is characterized by an increased Bax/Bcl-2 ratio, activation of Caspase-3/7/9, and increased Cleaved-PARP; this pro-apoptotic effect can be partially reversed by Z-VAD-FMK (HY-16658B). RR-171 also induces pyroptosis (Pyroptosis) in pancreatic cancer cells, which is manifested by activation of the NLRP-3 inflammasome, activation of Caspase-1, cleavage of GSDMD, upregulation of IL-1β and IL-18, and increased LDH release; this pro-pyroptotic effect can be partially reversed by VX-765 (HY-13205). RR-171 inhibits the viability, proliferation and colony formation of pancreatic cancer cells, with low cytotoxicity against normal cells. RR-171 downregulates the expression of Ki-67 and PCNA in tumor tissues in vivo, with favorable biosafety. RR-171 can be used in studies related to pancreatic cancer.
|
Wnt
Apoptosis
Pyroptosis
NOD-like Receptor (NLR)
Caspase
Bcl-2 Family
β-catenin
GSK-3
Interleukin Related
|
/
|
| HY-20457G | TL8-506 (GMP) |
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy.
|
|
/
|
| HY-P992351 | ELB021 |
ELB021 is an antibody inhibitor targeting the CD160 checkpoint. ELB021 specifically binds to CD160 on the cell surface and blocks its immune checkpoint pathway, thereby stimulating innate and adaptive anti-tumor immune responses. ELB021 effectively eliminates CD160-expressing cancer cells by enhancing T cell proliferation and CD8+ T cell-mediated cytotoxicity. Independent of PD-1 regulation, ELB021 is applicable to research related to B-cell leukemia and HIV-1 infection.
Species: Human |
|
/
|
| HY-P4890 | Relaxin H3 (human) |
Relaxin H3 (human) is a relaxin peptide with anti-inflammatory, anti-apoptotic, anti-pyroptotic, anti-migratory, protective and anti-fibrotic activities. Relaxin H3 (human) acts on RXFP1 to generate cAMP and reduce the levels of ATP and ROS. Relaxin H3 (human) inhibits renal inflammatory pyroptosis (pyroptosis), NLRP3 inflammasome activation, caspase-1 activation, IL-1β/IL-18 secretion, collagen synthesis, TGF-β1 signaling pathway, Smad2 phosphorylation, myofibroblast differentiation, TIMP expression, and HRMEC migration. Relaxin H3 (human) activates AMPK, upregulates MFN2 expression, improves mitochondrial quality control and membrane potential, inhibits apoptosis (apoptosis) and pyroptosis, restores retinal ultrastructure, and reverses excessive left ventricular collagen expression. Relaxin H3 (human) can be used in studies related to kidney stones, nephrocalcinosis, diabetic cardiomyopathy, fibrotic cardiomyopathy, and diabetic retinopathy.
|
RXFP Receptor
Reactive Oxygen Species (ROS)
Pyroptosis
Caspase
Interleukin Related
TGF-beta/Smad
AMPK
Apoptosis
|
/
|
| HY-122292 | Celastramycin A |
Celastramycin A is an antibiotic isolated from Streptomyces MaB-QuH-8, which exhibits antimicrobial activity against series of gram-negative bacteria and mycobacteria, with MICs between 0.05-3.1 μg/ml. Celastramycin A exhibits immunosuppressing efficacy in ex vivo Drosophila through immune deficiency pathway (IC50 of 0.008 μg/ml), inhibits the immunoresponse in human innate immunity through TNF-α signaling, inhibits IL-8 production in HUEVCs with IC50 of 0.06 μg/ml.
Source: Drosophila |
|
/
|
| HY-P2291A | Beta-defensin 103 isoform X1, pig TFA |
Beta-defensin 103 isoform X1, pig TFA is an antimicrobial peptide found in different living organisms, involved in the first line of defense in their innate immune response against pathogens.
|
|
/
|
| HY-N6714R | Alternariol (Standard) |
Alternariol (Standard) is the analytical standard of Alternariol. This product is intended for research and analytical applications. Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen Receptor) effects. Alternariol can induce apoptosis, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects.
|
|
/
|
| HY-N2902 | Artocarpin |
Artocarpin is an orally active apoptosis inducer. Artocarpin targets NF-κB, Erk1/2, p38 MAPK, AktS473, p53, Akt 1 kinase and Akt 2 kinase. Artocarpin induces reactive oxygen species (ROS) production, mediates p53-dependent and p53-independent apoptotic signaling pathways, induces G1-phase cell cycle arrest, and triggers autophagic cell death. Artocarpin exerts cytotoxic and bactericidal effects on cancer cells, reduces bacterial load, and exhibits anti-inflammatory, analgesic and anti-angiogenic activities.
|
|
/
|
| HY-16569B | Colchicine,suitable for plant cell culture |
Colchicine,suitable for plant cell culture, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine,suitable for plant cell culture can be used for plant cell culture.
|
|
/
|
| HY-P2457 | rCRAMP (rat) |
rCRAMP (rat) is the rat cathelin-related antimicrobial peptide. rCRAMP (rat) contributes to the antibacterial activity in rat brain peptide/protein extracts. rCRAMP (rat) is a potential key player in the innate immune system of rat CNS.
|
|
/
|
| HY-N12905 | Celastramycin A (isomer) |
Celastramycin A isomer is an isomer of Celastramycin A (HY-122292), an antibiotic against Gram-negative bacteria and Mycobacterium tuberculosis with an MIC of 0.05-3.1 μg/mL. Celastramycin A exerts immunosuppressive effects in Drosophila ex vivo via the immunodeficiency pathway (IC50 of 8 ng/mL), inhibits human innate immune responses via the TNF-α pathway, and inhibits IL-8 production in HUEVC with an IC50 of 60 ng/mL.
Source: Streptomyces strains |
|
/
|
| HY-147338S | 5-Methylcytidine 5′-triphosphate-d3 trisodium |
5-Methylcytidine 5′-triphosphate-d3 trisodium is the deuterium labeled 5-Methylcytidine 5’-triphosphate trisodium (HY-147338A). 5-Methylcytidine 5′-triphosphate (5-Methyl-CTP) trisodium is a modified nucleoside triphosphate. 5-Methylcytidine 5′-triphosphate trisodium can apply in replacing unmodified mRNA, resulting in the increase of translational properties and stability, as well as the reduction of innate immune responses in human and other mammalian cells.
|
|
/
|
| HY-N0546R | Ligustroflavone (Standard) |
Ligustroflavone (Standard) is the analytical standard of Ligustroflavone (HY-N0546). This product is intended for research and analytical applications. Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis.
|
Neurological, Eye or Ear Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-17355BS | Dexpramipexole-d3 dihydrochloride |
Dexpramipexole-d3 ((R)-Pramipexole-d3) dihydrochloride is the deuterium labeled Dexpramipexole. Dexpramipexole ((R)-Pramipexole) dihydrochloride is an orally active, blood-brain barrier permeable mitochondrial protective agent. Dexpramipexole dihydrochloride upregulates the expression of Parkin, PINK1, GPX4 and FSP1; binds to mitochondrial F1/Fo-ATP synthase; blocks the Nav1.8 sodium channel; and inhibits the activation of the NLRP3 inflammasome. Dexpramipexole dihydrochloride induces mitophagy, inhibits ferroptosis, pyroptosis, apoptosis, neuroinflammation and eosinophilopoiesis; maintains mitochondrial function and redox homeostasis; reduces reactive oxygen species production; and decreases myocardial infarct size. Dexpramipexole dihydrochloride is applicable to studies on eosinophilic asthma, myocardial ischemia/reperfusion injury, sepsis-associated encephalopathy, analgesia, and more.
|
Reactive Oxygen Species (ROS)
Isotope-Labeled Compounds
Glutathione Peroxidase
Ferroptosis
Apoptosis
Sodium Channel
Mitophagy
Autophagy
ATP Synthase
NOD-like Receptor (NLR)
PINK1/Parkin
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
|
/
|
| HY-N16463 | QS-S2 |
|
|
/
|
| HY-111582G | BBIQ (GMP) |
BBIQ (GMP) is BBIQ (HY-111582) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BBIQ is a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses.
|
|
/
|
| HY-D2376 | BH-Vis |
BH-Vis is a two-photon fluorescent probe that inhibits cell plasma membrane (CPM). BH-Vis has great potential to accurately identify pyroptosis at the cellular level during AAA development in the mouse abdominal aortic aneurysm AAA model.
|
|
/
|
| HY-N12641 | Ardisianone |
Ardisianone is a component with an alkyl benzoquinone structure that can be isolated from Ardisia virens Kurz and Ardisia compressa tea extract. Ardisianone exhibits potent antileukemic activity, particularly against HL-60 cells, with IC50 values of 1.87 μM (24 h) and 1.67 μM (48 h). Ardisianone induces caspase-dependent apoptosis and triggers pyroptosis. Ardisianone can be used for the study of acute myeloid leukemia (AML).
|
|
/
|
| HY-W031757R | Anthraquinone-2-carboxylic acid (Standard) |
Anthraquinone-2-carboxylic acid (Standard) is the analytical standard of Anthraquinone-2-carboxylic acid (HY-W031757). This product is intended for research and analytical applications. Anthraquinone-2-carboxylic acid is an orally active anthraquinone compound and Antibacterial agent. Anthraquinone-2-carboxylic acid can be isolated from Bajitian. Anthraquinone-2-carboxylic acid inhibits the activation of DPP-IV, COX-2, NF-κB and AP-1. Anthraquinone-2-carboxylic acid blocks IAV-induced activation of the RIG-I/STAT1 pathway, alleviates IAV-mediated weight loss, and protects against lethal IAV infection. Anthraquinone-2-carboxylic acid inhibits the growth of various Staphylococcus strains. It possesses potent anti-inflammatory, immunomodulatory, analgesic and antibacterial activities.\n
|
Reference Standards
Influenza Virus
Bacterial
Dipeptidyl Peptidase
COX
NF-κB
AP-1
RIG-I-like receptor (RLR)
STAT
|
/
|
| HY-32350S1 | Ercalcitriol-d3 |
Ercalcitriol-d3 (1α,25-Dihydroxy Vitamin D2-d3) is the deuterium labeled Ercalcitriol (HY-32350). Ercalcitriol (1α,25-Dihydroxy Vitamin D2) is a vitamin D receptor (VDR) agonist with high binding affinity. After binding to VDR, Ercalcitriol forms a complex with retinoid X receptor (RXR) to regulate target gene transcription. For example, Ercalcitriol induces human gingival/oral epithelial cells to produce human cat antimicrobial peptide (hCAP-18/LL-37), which has antimicrobial activity against periodontal pathogens such as Porphyromonas gingivalis. Ercalcitriol enhances the innate immune defense of the oral mucosa by promoting the expression of antimicrobial peptides, and is mainly used in the study of periodontal diseases and immune-related oral diseases.
|
|
/
|
| HY-W653896 | Alternariol-d2 |
Alternariol-d2 is deuterium labeled Alternariol. Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen Receptor) effects. Alternariol can induce apoptosis, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects.
|
|
/
|
| HY-B2176BR | ATP dimagnesium (Standard) |
ATP (dimagnesium) (Standard) is the analytical standard of ATP (dimagnesium). This product is intended for research and analytical applications. ATP (Adenosine 5'-triphosphate) dimagnesium is a central component of energy storage and metabolism in vivo. ATP dimagnesium provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP dimagnesium is an important endogenous signaling molecule in immunity and inflammation.
|
|
/
|
| HY-119684S | Maresin 2 |
Maresin 2-d5 is the d5-labeled Maresin 2 (HY-119684). Maresin 2 is an anti-inflammatory and pro-resolving mediator. Maresin 2 drives intestinal epithelial cell migration by activating the focal cell-matrix adhesion signaling pathway in primary human intestinal epithelial cells, thereby promoting mucosal wound repair. Maresin 2 alleviates nociceptive and anxiety-like behaviors in rats with type 1 diabetes by inhibiting IL-1β in the spinal cord and prefrontal cortex. Maresin 2 attenuates allergic airway inflammation in mice by inhibiting the activation of the NLRP3 inflammasome, Th2-type immune responses, and oxidative stress. Maresin 2 inhibits inflammatory and neuropathic trigeminal neuralgia and reduces neuronal activation in the trigeminal ganglion. Maresin 2 promotes inflammation resolution and mucosal repair after DSS-induced colitis or biopsy-induced colonic mucosal injury.
|
|
/
|
| HY-P2076A | Dusquetide TFA |
Dusquetide (SGX942) TFA is a first-in-class innate defense regulator (IDR). Dusquetide TFA modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide TFA shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
|
|
/
|
| HY-B2176S3 | ATP-15N5,d14 dilithium |
ATP-15N5,d14 (Adenosine 5'-triphosphate-ATP-15N5,d14) dilithium is the 15N5,d14-labeled ATP (HY-B2176). ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
Isotope-Labeled Compounds
Endogenous Metabolite
NOD-like Receptor (NLR)
Interleukin Related
Bacterial
|
/
|
| HY-112763 | CLinDMA |
CLinDMA, a cationic lipid, can cause inflammatory response. CLinDMA can be used for the synthesis LNP201. LNP201 is a liposome assembly for systemic delivery of siRNA.
|
|
/
|
| HY-144002 | RIBI-529 |
RIBI-529 (RC-529) is a fully synthetic, low-toxicity TLR4 agonist vaccine adjuvant. RIBI-529 upregulates cell surface co-stimulatory molecules, receptors, cytokines and chemokines, and activates the innate immune system. RIBI-529 enhances short-term CD4+ T cell clonal expansion, division, and ex vivo survival under growth factor withdrawal conditions. RIBI-529 enhances humoral and cell-mediated adaptive immune responses, induces non-specific resistance against viral and bacterial pathogens, and skews responses toward a Th1 type, accompanied by Th2 responses.
|
|
/
|
| HY-153939S | Idasanutlin-d3-1 |
Idasanutlin-d3-1 (RG7388-d3-1) is the deuterated-labeled Idasanutlin (HY-15676). Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors.
|
Isotope-Labeled Compounds
MDM-2/p53
E1/E2/E3 Enzyme
Apoptosis
Pyroptosis
Reactive Oxygen Species (ROS)
Caspase
Musculoskeletal and Skin Disease
Colorectal Cancer
Melanoma
Neuroblastoma
Osteosarcoma
Non-Small Cell Lung Cancer
Acute Myeloid Leukemia
Non-Hodgkin Lymphoma
|
/
|
| HY-P4890A | Relaxin H3 (human) TFA |
Relaxin H3 (human) TFA is a relaxin peptide with anti-inflammatory, anti-apoptotic, anti-pyroptotic, anti-migratory, protective and anti-fibrotic activities. Relaxin H3 (human) TFA acts on RXFP1 to generate cAMP and reduce the levels of ATP and ROS. Relaxin H3 (human) TFA inhibits renal inflammatory pyroptosis (pyroptosis), NLRP3 inflammasome activation, caspase-1 activation, IL-1β/IL-18 secretion, collagen synthesis, TGF-β1 signaling pathway, Smad2 phosphorylation, myofibroblast differentiation, TIMP expression, and HRMEC migration. Relaxin H3 (human) TFA activates AMPK, upregulates MFN2 expression, improves mitochondrial quality control and membrane potential, inhibits apoptosis (apoptosis) and pyroptosis, restores retinal ultrastructure, and reverses excessive left ventricular collagen expression. Relaxin H3 (human) TFA can be used in studies related to kidney stones, nephrocalcinosis, diabetic cardiomyopathy, fibrotic cardiomyopathy, and diabetic retinopathy.
|
RXFP Receptor
Reactive Oxygen Species (ROS)
Pyroptosis
Caspase
Interleukin Related
TGF-beta/Smad
AMPK
Apoptosis
|
/
|
| HY-141462 | 2',4-Dihydroxychalcone |
2',4-Dihydroxychalcone is an orally active natural chalcone flavonoid. 2',4-Dihydroxychalcone restores intestinal barrier integrity by upregulating tight junction proteins, regulates intestinal flora balance and alleviates inflammation. 2',4-Dihydroxychalcone induces GPX4 degradation, ferroptosis and apoptosis, triggers cell cycle arrest, and exhibits broad anti-tumor activity. 2',4-Dihydroxychalcone also possesses antifungal activity, antileishmanial activity, and reduces the hemolytic effect and virulence of Vibrio vulnificus.
|
Cancer
Inflammation or Immune System Disease
Bacterial Infection
Fungal Infection
Leishmania Infection
|
/
|
| HY-P5169A | LVGRQLEEFL (mouse) TFA |
LVGRQLEEFL (mouse) TFA can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) TFA exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) TFA can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death.
|
|
/
|
| HY-P992060 | Anti-Mouse CD20 Antibody (18B12) |
Anti-Mouse CD20 Antibody (18B12) is a B cell depleting agent that targets mouse CD20. Anti-Mouse CD20 Antibody (18B12) not only inhibits the growth of mesothelioma, lung cancer and thymoma, but also significantly enhances the efficacy of adenoviral tumor antigen vaccines and induces tumor regression by increasing the number of tumor-specific CD8+ T cells. Anti-Mouse CD20 Antibody (18B12) reduces B cell infiltration into the central nervous system of mice with experimental autoimmune encephalomyelitis, and delays motor dysfunction and neuronal death after spinal cord injury by alleviating inflammatory responses and tissue damage. Anti-Mouse CD20 Antibody (18B12) is widely applicable to research in fields related to mesothelioma, lung cancer, thymoma, experimental autoimmune encephalomyelitis and spinal cord injury.
Species: Mouse |
|
/
|
| HY-P991126 | Ciltistotug |
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy.
Species: Human |
|
/
|
| HY-P991125 | Cenzestotug |
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy.
Species: Human |
|
/
|
| HY-P2275B | Peptide5 TFA |
|
/
|
|
| HY-P99709 | Lodapolimab |
Lodapolimab (LY3300054) is a fully human IgG1λ anti-PD-L1 monoclonal antibody, with an EC50 of 0.075 nM against hPD-L1 and an EC50 of 0.085 nM against cynomolgus monkey PD-L1. Lodapolimab induces naive T cell activation, enhances the T cell activation effect of anti-CTLA4 antibodies, promotes anti-tumor alloreactivity, regulates innate immune pathways, and induces characteristics of adaptive immune activation. Lodapolimab can be used in research related to high-grade serous ovarian cancer and other solid tumors.
Species: Human |
|
/
|
| HY-P11603 | SK56 |
SK56 is a GSDMD-NT pore inhibitor. SK56 inhibits pyroptosis (Pyroptosis) and the release of pyroptosis-related cytokines in macrophages and human peripheral blood leukocytes. SK56 prevents extensive cell death in human alveolar organoids in an organoid-macrophage co-culture model. SK56 prevents death from infectious shock induced by LPS (HY-D1056) or cecal ligation and puncture in mice. SK56 can be used in studies related to sepsis.
|
|
/
|
| HY-W747928 | (-)-Aspartic acid-d3 |
(-)-Aspartic acid-d3 ((R)-Aspartic acid-d3) is the deuterium labeled (-)-Aspartic acid (HY-42068). (-)-Aspartic acid is a pyroptosis inhibitor. (-)-Aspartic acid acts as a neurotransmitter and neuromodulator, participates in hormone synthesis and regulation, and plays a role in nervous system development and endocrine system.
|
|
/
|
| HY-42068R | (-)-Aspartic acid (Standard) |
(-)-Aspartic acid (Standard) is the analytical standard of (-)-Aspartic acid. This product is intended for research and analytical applications. (-)-Aspartic acid is a pyroptosis inhibitor. (-)-Aspartic acid acts as a neurotransmitter and neuromodulator, participates in hormone synthesis and regulation, and plays a role in nervous system development and endocrine system.
|
|
/
|
| HY-150843S | ATP-15N5 ammonium |
ATP-15N5 (Adenosine 5'-triphosphate-ATP-15N5) ammonium is the 15N5-labeled ATP (HY-B2176). ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
|
/
|
| HY-P10217 | PD-1/PD-L1-IN-42 |
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC50 of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Ovarian Cancer
|
/
|
| HY-100573S | Necrosulfonamide-d4 |
Necrosulfonamide-d4 is the deuterium labeled Necrosulfonamide (HY-100573). Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
|
Isotope-Labeled Compounds
Mixed Lineage Kinase
Necroptosis
Pyroptosis
Caspase
NOD-like Receptor (NLR)
Keap1-Nrf2
TNF Receptor
Integrin
NO Synthase
Heme Oxygenase (HO)
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-P2320 | IDR-1 |
IDR-1 is an antimicrobial peptide that is active against Gram-positive and Gram-negative bacteria. IDR-1 counters infection by selective modulation of innate immunity without obvious toxicities. IDR-1 has anti-inflammatory and anti-infective properties, enhances the levels of monocyte chemokines, and attenuates pro-inflammatory cytokine release.
|
|
/
|
| HY-N9921 | Antcin A |
Antcin A is a potent NLRP3 inhibitor that inhibits the assembly and activation of the NLRP3 inflammasome. Antcin A can inhibit Kupffer cell pyroptosis and has liver protective activity. Antcin A can be used to study inflammation, such as non-alcoholic fatty liver disease.
Source: Antrodia cinnamomea |
|
/
|
| HY-P10862A | AH-D peptide TFA |
AH-D peptide TFA is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy.
|
|
/
|
| HY-B2176S7 | ATP-13C2 dilithium |
ATP-13C2 (Adenosine 5'-triphosphate-ATP-13C2) dilithium is the 13C2-labeled ATP (HY-B2176). ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
Isotope-Labeled Compounds
Endogenous Metabolite
NOD-like Receptor (NLR)
Interleukin Related
Bacterial
|
/
|
| HY-B2176S4 | ATP-d14 dilithium |
ATP-d14 (Adenosine 5'-triphosphate-ATP-d14) dilithium is the d14-labeled ATP (HY-B2176). ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
Isotope-Labeled Compounds
Endogenous Metabolite
NOD-like Receptor (NLR)
Interleukin Related
Bacterial
|
/
|
| HY-121362 | Evernic Acid |
Evernic Acid is an orally active thioredoxin reductase 1 (TrxR1) inhibitor and antiproliferative agent. Evernic Acid inhibits the proliferation and migration of human breast cancer cells. Evernic Acid blocks the NF-κB pathway by inhibiting p65 nuclear translocation and IκBα phosphorylation, thereby suppressing downstream inflammatory mediators. Evernic Acid acts as an antioxidant, anti-inflammatory agent and neuroprotective agent, protects neurons from cell death, mitochondrial dysfunction and oxidative stress damage, reduces astrocyte activation, and ameliorates dopaminergic neuron loss and neuroinflammation. Evernic Acid inhibits enoyl reductases FabI and FabZ of Plasmodium falciparum. Evernic Acid downregulates the expression of lasB and rhlA genes in Pseudomonas aeruginosa, inhibits quorum sensing and biofilm formation, and exerts antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and fungi. Evernic Acid is applicable to research related to breast cancer, Parkinson's disease, bacterial infections and fungal infections.
|
|
/
|
| HY-P10400A | AtPep1 TFA |
AtPep1 TFA is an endogenous inducer of innate immune responses. AtPep1 TFA can be isolated from Arabidopsis thaliana leaves. AtPep1 TFA activates the transcription of defensin (PDF1.2), the expression of PROPEP1, the synthesis of hydrogen peroxide (H2O2) near leaf veins, and the alkalization of Arabidopsis suspension cell culture medium. AtPep1 TFA induces the expression of genes encoding defensins and PR-1. AtPep1 TFA is applicable to studies related to Pythium irregulare infection and pathogen infection.
|
|
/
|
| HY-N6642 | Ankaflavin |
Ankaflavin, isolated from Monascus-Fermented red rice, is an orally active PPARγ agonist. Ankaflavin exhibits selective cytotoxic effect and induces cell death through apoptosis on cancer cells. Ankaflavin has anti-inflammatory, anti-cancer, antiatherosclerotic, and hypolipidemic effects.
Source: Monascus |
|
/
|
| HY-P99618 | Fidasimtamab |
Fidasimtamab is a bispecific antibody targeting human epidermal growth factor receptor 2 (Her2) and programmed death protein 1 (PD-1), with a Ka of 3.55e-10 M for human Her2 and a Ka of 1.17e-9 M for human PD-1. Fidasimtamab cross-links Her2-positive tumor cells with PD-1-positive T cells to form immune synapses, blocks PD-1-ligand interactions, preserves antibody-dependent cellular cytotoxicity, induces gasdermin B (GSDMB)-mediated pyroptosis, and activates T cells. Fidasimtamab is applicable to relevant research on Her2-positive gastric cancer.
Species: Human |
|
/
|
| HY-P3486 | GADGVGKSAL |
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research.
|
|
/
|
| HY-P3487 | GAGGVGKSA |
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
|
|
/
|
| HY-150709S | ATP-13C10,15N5 ammonium solution (100 mM) |
ATP-13C10,15N5 (Adenosine 5'-triphosphate-ATP-13C10,15N5) ammonium solution (100 mM) is the 13C10,15N5-labeled ATP (HY-B2176). ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
Isotope-Labeled Compounds
Endogenous Metabolite
NOD-like Receptor (NLR)
Interleukin Related
Bacterial
|
/
|
| HY-P990782 | Efzofitimod |
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD).
Species: Human |
|
/
|
| HY-B2123R | Lactose (Standard) |
Lactose (Standard) is the analytical standard of Lactose. This product is intended for research and analytical applications. Lactose is a β-galactoside consisting of galactose and glucose residues, the main carbohydrate in mammalian breast milk. Lactose, a macronutrient and an inducer of host innate immune responses, possesses immune modulatory functions.
|
|
/
|
| HY-P99928 | Efprezimod alfa |
Efprezimod alfa (MK 7110; CD24 Fc) is a humanized CD24-Fc fusion protein. Efprezimod alfa enhances the interaction between CD24 and Siglec-10, thereby regulating the response of innate immune cells to damage-associated molecular patterns, inhibiting the activation of antigen-presenting cells and subsequent inflammatory responses. Efprezimod alfa is applicable to the research of acute graft-versus-host disease and acquired immunodeficiency syndrome.
|
|
/
|
| HY-P99834 | Crefmirlimab |
Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research.
Species: Human |
|
/
|
| HY-N1420AR | Rhamnose monohydrate (Standard) |
Rhamnose monohydrate (Standard) is the analytical standard of Rhamnose monohydrate (HY-N1420A). Rhamnose monohydrate (L-Rhamnose monohydrate) is an orally active deoxysugar. Rhamnose monohydrate can inhibit levels of pro-inflammatory interleukin and matrix metalloproteinases (MMPs) in skin aging models. Rhamnose can promote the phosphorylation levels of PKA substrates and HSL in SVF-derived adipocytes, stimulating PKA signaling. Rhamnose monohydrate can act against obesity in mice by stimulating fat dopamine receptors and inducing thermogenesis. Rhamnose monohydrate shows anti-aging effects. Rhamnose monohydrate can be used in the study of Ehrlich’s solid tumors and sarcomas.
|
|
/
|
| HY-126113 | KIN101 |
KIN101 is a potent RNA viral inhibitor with IC50s of 2 μM, >5 μM for influenza virus and Dengue virus (DNV), respectively. KIN101, an isoflavone agonist of IRF-3 dependent signaling, induces IRF-3 nuclear translocation. KIN101 has broad-spectrum activity against RNA viruses.
|
|
/
|
| HY-P10424 | OPBP-1 |
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Ovarian Cancer
|
/
|
| HY-P3488 | GADGVGKSA |
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
|
|
/
|
| HY-111954 | (+)-Erinacin A |
(+)-Erinacin A (Erinacine A) is a cyanoditerpenoid isolated from Hericium erinaceus with anticancer, anti-inflammatory and neuroprotective activities. (+)-Erinacin A can induce cancer cell death by activating extrinsic and intrinsic apoptosis pathways. (+)-Erinacin A can also inhibit the expression of NO synthase (iNOS) and the production of nitrotyrosine to exert inflammatory and neuroprotective effects, thereby reducing ischemic brain damage.
Source: Hericium erinaceus |
|
/
|
| HY-W040255 | 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine |
1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine is an oxidized phospholipid. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine reduces the viability of HUVECs, increases the levels of ferrous ions and lipid peroxidation, promotes the production of superoxide anions, and decreases the levels of glutathione and GPX4 in cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine upregulates the mRNA and protein levels of FABP3 in HUVECs, impairs mitochondrial membrane potential, and induces ferroptosis-related changes as well as mitochondrial dysfunction and damage. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine activates caspase-11 and promotes the continuous release of IL-1β from macrophages and dendritic cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine inhibits the proliferation of aortic smooth muscle cells and induces apoptosis in these cells. 1-Palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine is applicable to relevant research on atherosclerosis.
|
|
/
|
| HY-P99484 | Botensilimab |
|
/
|
|
| HY-N5025 | Bullatine A |
Bullatine A, a diterpenoid alkaloid, is a potent P2X7 antagonist. Bullatine A possesses anti-rheumatic, anti-inflammatory and anti-nociceptive effects. Bullatine A inhibits ATP-induced BV-2 cell death/apoptosis and P2X receptor-mediated inflammatory responses. Bullatine A suppresses glioma cell growth by targeting SIRT6. Bullatine A specifically attenuates pain hypersensitivity in rats. Bullatine A attenuates LPS (HY-D1056)-induced systemic inflammatory response by inhibiting the ROS/JNK/NF-κB pathway in mice. Bullatine A improves despair behavior in Chronic chronic social defeat stress (CSDS) mice. Bullatine A can be used for the study of inflammation, glioblastoma (GBM) and depression.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Neurodegenerative Disease
Depression
Pain
Digestive System Inflammation
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
/
|
| HY-P11058 | OVA(250-264) |
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8+ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research.
|
|
/
|
| HY-101092A | QS-21 |
|
/
|
|
| HY-123805 | KIN1400 |
KIN1400 is a potent IRF3 activator. KIN1400 triggers IRF3-dependent innate immune antiviral genes (RIG-I, MDA5, IFIT1, and Mx1) and IFN-β expression. KIN1400 inhibits WNV and DV, two mosquito-borne members of the Flaviviridae and the genus Flavivirus. KIN1400 also inhibits HCV replication. KIN1400 induces innate antiviral immunity through a MAVS-IRF3 axis.
|
|
/
|
| HY-159114 | Whole Glucan Particles |
Whole Glucan Particles is a Dectin-1a agonist. Whole Glucan Particles activates the innate immune system to improve the function of macrophages, monocytes and other immune cells.
|
|
/
|
| HY-P990068 | Perenostobart |
Perenostobart (SRF617) is a human IgG4 antibody with inhibitory activity against CD39 ATPase. Perenostobart inhibits CD39-mediated hydrolysis of extracellular ATP to AMP, with IC50 values of 1.9 nM (HEK293 OE cells), 0.7 nM (MOLP-8 cells), and 1.2 nM (RBC-lysed whole blood). Perenostobart enhances CD4+ T-cell proliferation, promotes dendritic cell maturation, and boosts inflammasome activation in macrophages in the presence of ATP. Perenostobart demonstrates significant single-agent anti-tumor efficacy in MOLP-8 and H520 xenograft models. Perenostobart can be used for the study of cancer.
Species: Human |
|
/
|
| HY-P10939A | Ac-DMLD-CMK TFA |
Ac-DMLD-CMK TFA is a caspase 3 inhibitor and a GSDME inhibitor. Ac-DMLD-CMK TFA binds directly to the catalytic domain of caspase-3, blocks caspase-3-mediated cleavage of GSDME, inhibits the activation of caspase 3 and Gsdme in the caspase 3-Gsdme signaling pathway, and reduces the levels of pyroptosis and apoptosis as well as the expression of LDH, IL-6, IL-1β and IL-18. Ac-DMLD-CMK TFA alleviates renal function deterioration, renal tubular epithelial cell injury, inflammatory cytokine secretion, pulmonary structural damage, and chemotherapy-induced nephrotoxicity.
|
|
/
|
| HY-139410 | Sodium caseinates |
Sodium caseinates is a kind of sodium salts of major milk proteins, which act as protein-based biopolymers and innate immune system activators. Sodium caseinates induce granulopoiesis, activation and differentiation, promote the production of M-CSF, and increase serum levels of G-CSF and GM-CSF. Sodium caseinates inhibit the proliferation and reduce the viability of leukemia macrophage-like cells, thereby significantly improving the survival rate of mice inoculated with leukemia cells. Sodium caseinates can serve as carriers for probiotics in edible films and exhibit anti-Listeria activity. Sodium caseinates effectively protect vitamin A from degradation, enhance its stability, bioaccessibility and bioavailability, and regulate protein digestibility when complexed with vitamin A. Sodium caseinates can be applied to research related to acute monocytic leukemia and vitamin A deficiency.
|
|
/
|
| HY-150709S1 | ATP-13C10,15N5 dilithium |
ATP-13C10,15N5 (Adenosine 5'-triphosphate-ATP-13C10,15N5) dilithium is the 13C10,15N5-labeled ATP (HY-B2176). ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
Isotope-Labeled Compounds
Endogenous Metabolite
NOD-like Receptor (NLR)
Interleukin Related
Bacterial
|
/
|
| HY-P10950A | PD-L1 inhibitory peptide TFA |
PD-L1 inhibitory peptide TFA is an inhibitor targeting the PD-1/PD-L1 interaction. PD-L1 inhibitory peptide TFA inhibits the PD-1-mediated apoptosis signaling pathway, maintains the survival and activity of T cells, activates the anti-tumor effect of cytotoxic T lymphocytes, and significantly improves the survival rate of mice in fungal sepsis models. PD-L1 inhibitory peptide TFA can be used for research on sepsis, breast cancer and other related diseases, as well as immunotherapy.
|
|
/
|
| HY-P2617A | Ac-WEHD-AFC TFA |
|
/
|
|
| HY-W007328 | 5-Methoxyindole |
5-Methoxyindole is an L-tryptophan metabolite with antifungal activity, and also serves as a pharmaceutical intermediate. Metabolites of 5-Methoxyindole exhibit COX-2 inhibitory, anti-inflammatory and anti-tumor activities. 5-Methoxyindole induces morphological distortion of hyphae and conidia, ROS accumulation, apoptosis and cell death in Gaeumannomyces graminis. 5-Methoxyindole can be used in studies related to fungal infections and organic synthesis.
|
|
/
|
| HY-N6714 | Alternariol |
Alternariol is an orally ingested mycotoxin produced by Alternaria, capable of inhibiting the activity of topoisomerase I and II (topoisomerase I, topoisomerase II). Alternariol has weak estrogenic (Estrogen Receptor/ERR) and androgen/antiandrogen (Androgen Receptor) effects. Alternariol can induce apoptosis, trigger cell cycle arrest, suppress innate immune responses, and exhibit anti-tumor activity. Alternariol has genotoxic, mutagenic, and endocrine-disrupting effects.
Source: fungi of the genus Alternaria |
|
/
|
| HY-N0891 | Tubeimoside II |
Tubeimoside II is an orally active triterpenoid saponin and antiviral agent that binds to PACT/PRKRA with Kd values of 5.37 μM and 133.1 μM, respectively. Tubeimoside II inhibits oxidase-dependent EGFR activation and reduces TGF-β1-induced oxidative stress. Tubeimoside II activates the RIG-I signaling pathway and increases IFN-β secretion. Tubeimoside II suppresses TPA-induced ear edema, mouse sarcoma 180 growth, and TPA-induced skin tumor formation. Tubeimoside II exerts broad-spectrum antiviral activity against SARS-CoV-2, HCoV-OC43, and IAV-H1N1/FM1. Tubeimoside II can be used in research related to retinoblastoma, respiratory viral infections, skin tumors, and sarcoma 180.
|
|
/
|
| HY-W031757 | Anthraquinone-2-carboxylic acid |
Anthraquinone-2-carboxylic acid is an orally active anthraquinone compound and Antibacterial agent. Anthraquinone-2-carboxylic acid can be isolated from Bajitian. Anthraquinone-2-carboxylic acid inhibits the activation of DPP-IV, COX-2, NF-κB and AP-1. Anthraquinone-2-carboxylic acid blocks IAV-induced activation of the RIG-I/STAT1 pathway, alleviates IAV-mediated weight loss, and protects against lethal IAV infection. Anthraquinone-2-carboxylic acid inhibits the growth of various Staphylococcus strains. It possesses potent anti-inflammatory, immunomodulatory, analgesic and antibacterial activities.\n
|
Inflammation or Immune System Disease
Pain
Influenza Virus Infection
Staphylococcus Aureus Infection
|
/
|
| HY-N2909 | Aurantiamide |
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as RIPK3/MLKL signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Cardiovascular Disease
Alzheimer's Disease
Parkinson's Disease
Obesity
|
/
|
| HY-P3151 | Gliadin p31-43 |
Gliadin p31-43 is an undigested gliadin peptide. Gliadin p31-43 induces an innate immune response in the intestine and interferes with endocytic trafficking. Gliadin p31-43 can be used for celiac disease research.
|
|
/
|
| HY-P99791 | Orilanolimab |
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity.
Species: Human |
|
/
|
| HY-P99759 | Nogapendekin alfa (his tag) |
Nogapendekin alfa his tag is an immunostimulant that binds to the IL-2RβγC complex on immune cells. Nogapendekin alfa his tag stimulates the proliferation and activation of natural killer cells and CD8+ T cells, upregulates the expression of granzyme B and perforin, and activates the innate and adaptive immune branches. Nogapendekin alfa his tag forms ALT-803 with IL-15RαSuFc; this complex has an extended biological half-life, improved biodistribution and retention in lymphoid tissues, enhances natural killer cell-mediated rituximab-dependent cellular cytotoxicity, and reduces tumor burden and improves survival when combined with anti-CD20 monoclonal antibody therapy. Nogapendekin alfa his tag can be used in the research of non-Hodgkin's lymphoma.
Species: Human |
|
/
|
| HY-P2076 | Dusquetide |
Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
|
|
/
|
| HY-145121 | DS96432529 |
DS96432529 is an orally active CDK8 inhibitor with an IC50 of 33 nM. DS96432529 enhances ALPase activity, with an EC200 of 63 nM. DS96432529 inhibits TNF-α-induced activation of the RLR signaling pathway, activates mitophagy, accelerates mineralized nodule formation, and suppresses the proliferation of periodontal ligament stem cells. DS96432529 promotes bone formation, alleviates ligation-induced alveolar bone loss, and increases bone mineral density in ovariectomized animal models. DS96432529 can be used in studies related to periodontitis and osteoporosis.
|
|
/
|
| HY-107202GL | Polyinosinic-polycytidylic acid (GMP Like) |
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
|
|
/
|
| HY-N0660 | Jujuboside B |
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway. Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.
|
Apoptosis
PARP
Caspase
AMPK
Autophagy
VEGFR
Keap1-Nrf2
STING
11β-HSD
Ferroptosis
PI3K
Akt
p38 MAPK
ERK
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
Breast Cancer
Colorectal Cancer
Leukemia/Lymphoma/Myeloma
Depression
Non-Small Cell Lung Cancer
|
/
|
| HY-16059 | Arglabin |
Arglabin ((+)-Arglabin), a natural product isolated from Artemisia glabella, is a NLRP3 inflammasome inhibitor. Arglabin shows anti-inflammatory and antitumor activities. The antitumor activity of Arglabin proceeds through its inhibition of farnesyl transferase which leads to the activation of RAS proto-oncogene.
|
|
/
|
| HY-B2176S6 | ATP-13C10 dilithium |
ATP-13C10 (Adenosine 5'-triphosphate-ATP-13C10) dilithium is the 13C10-labeled ATP (HY-B2176). ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
Isotope-Labeled Compounds
Endogenous Metabolite
NOD-like Receptor (NLR)
Interleukin Related
Bacterial
|
/
|
| HY-42068 | (-)-Aspartic acid |
(-)-Aspartic acid is a pyroptosis inhibitor. (-)-Aspartic acid acts as a neurotransmitter and neuromodulator, participates in hormone synthesis and regulation, and plays a role in nervous system development and endocrine system.
|
|
/
|
| HY-NP0204 | MSA Protein |
MSA Protein (Mouse Serum Albumin) is most abundant protein in plasma, which leaks into the brain parenchyma when the blood-brain barrier (BBB) is impaired. Mouse Serum Albumin induces astrocytes to A1 phenotype to remarkably increase levels of Elovl1. Mouse Serum Albumin promotes VLSFAs secretion and causes neuronal lippoapoptosis through endoplasmic reticulum stress response pathway. MSA-activated microglia triggeres remarkable tau phosphorylation at multiple sites (Ser202/Thr205) through NLRP3 inflammasome pathway. Mouse Serum Albumin decreases the spatial learning and memory abilities in mice. Mouse Serum Albumin can be used for the study of neurodegenerative diseases like Alzheimer’s disease (AD) and frontotemporal dementia (FTD).
|
|
/
|
| HY-P991049 | Atrosimab |
Atrosimab is an Fv-Fc1K fusion protein with an EC50 value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis.
Species: Human |
Experimental Autoimmune Encephalomyelitis
Experimental Autoimmune Encephalomyelitis
Fatty Liver Disease
|
/
|
| HY-P1934A | Cyclo(L-Phe-L-Pro) |
Cyclo(L-Phe-L-Pro), isolated from Pseudomonas fluorescens and Pseudomonas alcaligenes cell-free culture supernatants is an antifungal cyclic dipeptide. Cyclo(L-Phe-L-Pro) inhibits IFN-β production by interfering with retinoic-acid-inducible gene-I (RIG-I) activation. Cyclo(L-Phe-L-Pro) exhibits free-radical scavenging activity with the IC50 of 24 µM in the DPPH assay.
Source: Human pathogen Vibrio vulnificus |
|
/
|
| HY-P99175 | KWAR 23 |
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.
Species: Human |
|
/
|
| HY-157442 | GLPG3312 |
GLPG3312 (Compound 28) is an orally active SIK inhibitor with IC50 values of 2.0 nM, 0.7 nM and 0.6 nM for SIK1, SIK2 and SIK3, respectively. GLPG3312 exhibits anti-inflammatory and immunomodulatory activity in vitro on human primary myeloid cells and in vivo in mouse models. GLPG3312 has good oral bioavailability and can be used for research on inflammatory and immune diseases.
|
Salt-inducible Kinase (SIK)
Discoidin Domain Receptor
RIP kinase
LIM Kinase (LIMK)
MAP3K
Bcr-Abl
Src
TGF-β Receptor
|
/
|
| HY-P99396 | Spesolimab |
Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways.
Species: Human |
|
/
|
| HY-P991097 | Pumitamig |
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
Species: Human |
|
/
|
| HY-B2176R | ATP (Standard) |
ATP (Adenosine 5'-triphosphate) (Standard) is the analytical standard of ATP (HY-B2176). This product is intended for research and analytical applications. ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.
|
|
/
|
| HY-P71855 | RIPK3 Protein, Human (P.pastoris, His) |
RIPK3 is a kinase that controls necroptosis and apoptosis. In necroptosis, activated by TNF-α and ZBP1, RIPK3 phosphorylates MLKL, leading to membrane damage. RIPK3 Protein, Human (P.pastoris, His) is the recombinant human-derived RIPK3 protein, expressed by P. pastoris , with N-6*His labeled tag.
Species: Human; Source: P. pastoris |
|
/
|
| HY-P72170 | DDX58 Protein, Human (His) |
The DDX58 protein is an innate immune receptor that detects cytoplasmic viral nucleic acids and initiates a signaling cascade for type I interferon production.It forms ribonucleoprotein complexes with viral RNA and promotes homo-oligomerization.DDX58 Protein, Human (His) is the recombinant human-derived DDX58 protein, expressed by E.coli , with N-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P71853 | RIPK3 Protein, Mouse (P.pastoris, His) |
RIPK3 Protein, participates in programmed necrosis (necroptosis) and apoptosis, contributing to diverse cellular processes. RIPK3 Protein, Mouse (P.pastoris, His) is the recombinant mouse-derived RIPK3 protein, expressed by P. pastoris , with N-6*His labeled tag.
Species: Mouse; Source: P. pastoris |
|
/
|
| HY-P704049A | GSDMD Protein, Human (C-His) |
GSDMD Protein, Human (C-His) is the recombinant human-derived GSDMD protein, expressed by E. coli, with C-6*His tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P704049 | GSDMD Protein, Human (His) |
GSDMD Protein, Human (His) is the recombinant human-derived GSDMD protein, expressed by E. coli, with N-6*His tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P701552 | RNF135 Protein, Human |
The RNF135 protein acts as an E2-dependent E3 ubiquitin protein ligase and serves as a RIGI coreceptor for viral RNA sensing and activation of antiviral innate immune responses. RNF135 Protein, Human is the recombinant human-derived RNF135 protein, expressed by E. coli , with tag free.
Species: Human; Source: E. coli |
|
/
|
| HY-P705636 | RIPK3 Protein, Human (Active, sf9, GST) |
RIPK3 is a kinase that controls necroptosis and apoptosis. In necroptosis, activated by TNF-α and ZBP1, RIPK3 phosphorylates MLKL, leading to membrane damage. RIPK3, Human (Active, sf9, GST) is the recombinant human-derived RIPK3 protein, expressed by Sf9 insect cells, with labeled tag.
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P701553 | RNF135 Protein, Human (His) |
The RNF135 protein acts as an E2-dependent E3 ubiquitin protein ligase and serves as a RIGI coreceptor for viral RNA sensing and activation of antiviral innate immune responses. RNF135 Protein, Human (His) is the recombinant human-derived RNF135 protein, expressed by E. coli , with N-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P86351 | RIP3 Antibody (YA6043) |
RIP3 Antibody (YA6043) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RIP3.
Host: Rabbit; Reactivity: Mouse |
|
/
|
| HY-P82654 | MDA5 Antibody (YA2399) |
MDA5 Antibody (YA2399) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MDA5.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P82573 | DDX58 Antibody (YA2318) |
DDX58 Antibody (YA2318) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to DDX58.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P80979 | HOPX Antibody (YA846) |
HOPX Antibody (YA846) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HOPX.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P810298 | Vac14 Antibody |
Vac14 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Vac14.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P810290 | Phospho-RIP3 (S232) Antibody (YA9633) |
Phospho-RIP3 (S232) Antibody (YA9633) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RIP3.
Host: Rabbit; Reactivity: Mouse |
|
/
|
| HY-P810537 | Phospho-RIP3 (Ser232) Antibody (YA9807) |
Phospho-RIP3 (Ser232) Antibody (YA9807) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-RIP3 (Ser232).
Host: Rabbit; Reactivity: Mouse, Rat |
|
/
|
| HY-P87866 | MDA5 Antibody (YA7551) |
MDA5 Antibody (YA7551) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to MDA5.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P810290A | Phospho-RIP3 (S232) Antibody (YA9633)(PBS only) |
Phospho-RIP3 (S232) Antibody (YA9633) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RIP3.
Host: Rabbit; Reactivity: Mouse |
|
/
|
| HY-P83877 | DDX58 Antibody (YA3574) |
DDX58 Antibody (YA3574) is a Mouse-derived and non-conjugated IgM monoclonal antibody, targeting to DDX58.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P80979A | HOPX Antibody (YA846)(PBS only) |
HOPX Antibody (YA846) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HOPX.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P83706A | GSDMD Antibody (YA3443)(PBS only) |
GSDMD Antibody (YA3443) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to GSDMD.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P83877A | DDX58 Antibody (YA3574)(PBS only) |
DDX58 Antibody (YA3574) is a Mouse-derived and non-conjugated IgM monoclonal antibody, targeting to DDX58.
Host: Mouse; Reactivity: Human |
|
/
|
Targets/Pathways








































.jpg)












































































































































